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Abbreviation 
 
Abbreviation Full name 
AEs Adverse events 
ALT Alanine-aminotransferase 
ALP Alkaline phosphatase 
Bili Bilirubin 
CHC Chronic hepatitis C 
CI Confidence interval 
Crea Creatinine 
DAA Direct-acting antivirals 
DAC Daclatasvir 
EASL European Association for the Study of the Liver 
EOT End of treatment response 
EBR Elbasvir 
Epclusa Sofosbuvir /Velpatasvir  
EIA Enzyme Immunoassay 
EVR Early virological response 
FAD US Food and Drug Administration 
GT Genotype 
GZR Grazoprevir 
GZR/EBR Grazoprevir /Elbasvir  (Zepatier) 
Harvoni Sofosbuvir /Ledipasvir  
HB Hemoglobin 
HCC Hepatocellular carcinoma 
IFN Interferon 
IFN-free Interferon-free 
INR International normalized ratio  
LC Liver cirrhosis 
LDV Ledipasvir 
LTx Liver transplantation 
NS  nonstructural 
NTx Nephrectomy  
PCR Polymerase chain reaction 
PEG IFN Pegylated interferon 
Peg-IFN-α Peginterferon alfa-2a 
PI Protease inhibitor 
PLT Platelet, Thrombocytes 
RAS resistance-associated variant 
RBV Ribavirin 
RDTs Rapid diagnostic tests 
RVR Rapid virological response 
SOF Sofosbuvir 
SOF/DAC Sofosbuvir/ Daclatasvir  
SOF/EBR Sofosbuvir/Elbasvir  (Zepatier®) 
SOF/LDV Sofosbuvie/Ledipasvir  (Harvoni®) 
SOF/SMP Sofosbuvir /Simeprevir  
SOF/VEL Sofosbuvir/Velpatasvir  (Epclusa®) 
SMP Simeprevir 
SVR Sustained virological response 
TBIL Total bilirubin 
VEL Velpatasvir 
WBC White blood cell, Leukocytes 
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1.  Introduction 
 
1.1.  HCV molecular biology 
1.1.1.  Hepatitis C virus structure 
Hepatitis C virus was first discovered in 1989 and before this kind of hepatitis 
was called "non-A, non-B" hepatitis (NANBH). Hepatitis C virus is a number of the 
Flaviviridae family (Bennett et al., 2014). The virus size is 40-50 nm diameter, 
including 9600 nucleotides, and it is positive sense single-strand RNA (Bennett et al., 
2014, Neumann et al., 1998). The hepatitis C virus includes the core and lipid 
envelope.  Glycoproteins (E1 and E2) are embedded in the lipid envelope. The core 
consists of the RNA genome which surrounding by nucleocapsid.  
Hepatitis C virus protein consists of structural proteins and nonstructural proteins. 
Structural proteins include core protein, glycoproteins (E1 and E2) and p7 protein; 
Nonstructural proteins include NS2, NS3, NS4A, NS4B, NS5A, NS5B (Ashfaq et al., 
2011). 
HCV core protein consists of 191 amino acids which can be divided into three 
domains according to hydrophobicity (Bukh et al., 1994). HCV envelope 
glycoproteins are composed of two kinds of proteins, that is E1 and E2, which highly 
glycosylated, and play a critical role in entering cell process. The function of E1 is to 
fuse subunit, and E2 is the receptor of subunit binding in the envelope (Drummer et 
al., 2003). P7 protein is located between E2 and NS2, it is a polypeptide including 
63-amino acids. The function of the P7 protein is to build ion channels which play an 
important role in virus infection process (Griffin et al., 2003), and it is also necessary 
for virus assembling and infectious virions releasing in a special genotype (Griffin et 
al., 2003). NS2 is a transmembrane protein which is essential for the viral replication 
process in vivo and in vitro (Pietschmann et al., 2006). The NS3 protein has 
multifunctional activity, N-terminal of NS3 with serine protease activity, and a 
C-terminal of NS3 has NTPase/helicase activity (Gallinari et al., 1998). NS3 protease 
also plays a role in the division between NS3/4A, 4A/4B, 4B/5A and 5A/5B 
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(Bartenschlager et al., 1993). NS4A protein is a cofactor of NS3 protein. The 
interaction between NS4A and NS3  can activate the NS3 active site and promote 
protease cleavage (Kim et al., 1996). NS4B is a  hydrophobic protein contains four 
transmembrane domains, which play a critical role in other viral proteins recruitment. 
NS4B can interact with NS4A directly and interact with NS3 and NS5A indirectly 
(Lin et al., 1997). NS5A is a hydrophilic phosphoprotein without transmembrane 
domains. NS5A plays a critical role in viral replication, it also acts on interferon 
response and cell signaling pathways modulation (Macdonald et al., 2004, Reed et al., 
1997), and it is related to lipid droplets. NS5A Mutations are essential for viral 
replication and cell line replicons (Lohmann et al., 1999). NS5B structural is 'right 
hand' shape polymerase with finger and palm, and thumb sub domains surrounding 
encircled active site (Lesburg et al., 1999). NS5B is an RNA dependent polymerase 
and plays a critical role in new RNA genome synthesis, and also is essential for 
polymerase activity (Behrens et al., 1996). As a key component of the HCV 
replication, NS5B has become a major antiviral target (Njoroge et al., 2008). 
 
 
Fig. 1.  Hepatitis C virus structure (Perrault and Pécheur, 2009)  
 
3 
 
 
1.1.2 .  HCV Genotypes 
HVB is divided into seven genotypes and multiple subtypes (Nakano et al., 2012). 
However, patients are usually only infected with a single genotype, in samples of 
HCV infected patients, a mixture of closely related viruses referred to as quasispecies. 
This so called quasispecies constantly change the genomic sequence during the course 
of the infection. These changes make the development of a vaccine difficult.  
Epidemiological studies of hepatitis C patients from 98 countries worldwide 
demonstrated genotype 1 is the most common (46%), followed by genotype 3 (22%), 
genotype 2 (13%), genotype 4 (13%), genotype 6 (2%), and genotype 5 (1%) (Gower 
et al., 2014). The percentage of combination or undefined genotypes is 3%, among 
them, the most common subtype is genotype 1 ( 22% ) (Gower et al., 2014). 
Genotype has significant regional differences. The main genotype in Europe, 
North America, and Latin America is genotype 1 (62–71%), Genotype 1b accounting 
for 26%-71%. However, Genotype 4 proportion is large in the Middle East and North 
Africa (71%). In Asian countries，Genotype 3 proportion is 39%, followed by 
Genotype 1 (36%) (Gower et al., 2014). 
Vermehren et al. screened 20,809 hepatitis C infected patients in two cities of 
Germany (Berlin and Frankfurt), found that the genotype 1 account for 66%, followed 
by G3 (19% ) and G2 (5%).(Vermehren et al., 2012) 
    
1.1.3.  HCV Life cycle 
Replication of Hepatitis C virus involves several complex processes and mainly 
take place in liver hepatocytes. Each infected cell generates about 50 virus particles 
per day, and a total of one trillion virions can be synthesized (Bartenschlager and 
Lohmann, 2000). The virus also can replicate in mononuclear cells of peripheral 
blood, this may influence the immunological disorders of chronical HCV infected 
patients. Many kinds of virus variants are produced by the high mutation rate and lead 
to wide variety of mutates and genotypes of HCV (Bartenschlager and Lohmann, 
2000). 
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The Hepatitis C life cycle includes: entry, uncoating, translation and replication, 
assembly and release (Dubuisson and Cosset, 2014). 
During entry and uncoating process, the hepatitis C virus combined with 
lipoproteins form lipo Viro particles. The viral life cycle starts by binding with SRB1 
and GAGs (glycosaminoglycans) The virus follows a series of complicated process, 
this involves multiple cell entry factors, such as CD81, SRB1, CLDN1, OCLN, 
NPC1L1, EGFR, TfR (transferrin receptor), tight-junction proteins and signaling 
proteins. After binding to the host cell, the virus is internalized by endocytosis of 
clathrin, the fusion starts at this stage (Dubuisson and Cosset, 2014). HCV 
glycoproteins（E1 and E2）are the critical determinants of viral entry, which act as 
receptors between the host cell and viral envelope in the fusion process (Douam et al., 
2014). 
When the polyprotein cleavage, the virus nonstructural proteins combined with 
cellular factors form the replication complex, this causes the formation of the 
membranous web (double membrane vesicles), where replication occurs. After 
cleavage virus C-terminus, core protein is loaded upon LDs. The site of the virus 
assembly is at the junction between ER membranes and LDs. NS5A and NS3/4A 
assist new replicated viral genomes transfer to the assembly sites. The replication 
complexes and core proteins are connected to the glycoproteins by P7 and NS2. NS5B 
is the essential enzyme for RNA synthesis, translating RNA genome to produce new 
proteins, act as new RNA replication templates and assemble to form the new viruses 
(Dubuisson and Cosset, 2014, Scheel and Rice, 2013).  
Virus budding is assisted by the endosomal sorting complexes required for 
transport (ESCRT) (Ariumi et al., 2011). The ESCRT  machinery assists in vesicles 
budding and release from the cytoplasm, and is involved in the multivesicular bodies 
formation (Welsch et al., 2007). After assembly and budding in the endoplasmic 
reticulum, viral particles are released from cells by the secretory pathway (Coller et 
al., 2012).  The virions acquire low buoyant density characteristic during this process 
(Gastaminza et al., 2008, Gastaminza et al., 2006). Meanwhile, the glycans which are 
associated with the envelope glycoproteins are modified (Vieyres et al., 2010). 
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Fig. 2.  HCV life cycle (Scheel and Rice, 2013) 
 
1.2.  Prevalence of Hepatitis C infection 
Hepatitis C is one of the main cause leading to liver cirrhosis, liver failure, cancer 
and death in liver disease patients. A total of 185 million people are infected with 
hepatitis C worldwide. In the past decade, the seroprevalence as a whole is estimated 
around to 2.8% (Mohd Hanafiah et al., 2013). The latest data from the World Health 
Organization (WHO) show that hepatitis C infection mortality continues to increase in 
recent years. Only in one year like 2015, there are 1.75 million newly infected 
patients with hepatitis C (WHO, 2017). Epidemics of European countries data shows 
15 million people (1.6% of the population) are infected with Hepatitis C (WHO, 
2017). Globally, the largest HCV population live in China, which up to 29.8 million 
HCV infected people. The highest HCV prevalence could be detected in Egypt (>10%) 
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(WHO, 2017). The number of HCV patients in Asian countries accounts for half of 
the world's HCV population (Hajarizadeh et al., 2013). Vermehren et al. statistical 
analysis from the hepatitis C screening in two representative cities of Germany, 
showed that HCV seropositivity was up to 2.6% (Berlin 2.4%, Frankfurt 3.5%) 
(Vermehren et al., 2012). 
 
1.3.  Epidemiology of HCV infection 
Hepatitis C infection is mainly through the blood transmission, the proportion of 
sexual transmission and vertical transmission are not significant (Shepard et al., 2005).   
In comparison to hepatitis B virus sexual or perinatal transmission of HCV is much 
more infrequent. The risk to acquire HCV from breast feeding is negligible and spread 
within families is rare. 
Drug addicts and blood transfusions are high-risk groups population (Shepard et 
al., 2005). Cross-infection in hospitals, tattoos, acupuncture are also part of the 
transmission route (Alter, 2011). 
 
1.4.  Symptoms of hepatitis C infected patients 
Thepatitis C incubation period is two weeks to six months. At the initial stage of 
the infection, about 80% of patients do not have any symptoms or symptoms are not 
obvious. Patients with acute symptoms may have a fever, fatigue, loss of appetite, 
nausea, vomiting, abdominal pain, dark urine, joint pain, yellow skin. When hepatitis 
C infection develops to liver cirrhosis, the patient symptoms become more obvious. 
At the end-stage of hepatitis C patient, the symptoms may be with gastrointestinal 
bleeding, weakness, wasting and jaundice (Hoofnagle, 1997). 
 
1.5.  Diagnosis of Hepatitis C Virus Infection 
The real-time PCR is a sensitive method of quantifying HCV RNA levels from 10 
IU/mL to 100 million IU/mL. The unit of HCV RNA is IU/mL which was 
standardized by the World Health Organization (Saldanha et al., 2005), The HCV 
PCR assay is faster and more accurate than the other techniques (Barbeau et al., 2004).  
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HCV RNA level more than 800 000 IU/mL is defined as high viral load, and a low 
viral load is defined as less than 800 000 IU/mL (Pawlotsky et al., 2000). A clinical 
study found that patients with more than 2,000,000 IU/mL baseline viral load had a 
lower sustained virological response rate than those with less than 2,000,000 IU/mL 
(McHutchison et al., 1998).  
In addition to real-time PCR, other methods apply to for screening and diagnosing 
hepatitis C infection. The basic diagnostic test for HCV infection is anti-HCV 
antibodies. Anti-Hepatitis C Virus IgG, immunoblot assays, immunoassays（EIA）are 
used to identify hepatitis C infections (Kamili et al., 2012).  
A confirmed positive HCV antibody test, however, cannot distinguish between 
acute, chronic or past infection. Assays for HCV-lgM antibody detection have not 
proved to be useful. 
Nucleic Acid Amplification Testing (NAT) is the method to detect the presence of 
HCV RNA. Nucleic acid tests can be performed qualitatively and quantitatively. The 
qualitative polymerase chain reaction (PCR) and transcription-mediated amplification 
(TMA) are qualitative tests. The real-time PCR, bDNA (branched DNA) and 
quantitative reverse transcription–PCR are classified to quantitative tests. NATs are 
most common qualitative tests which use reverse transcription PCR to detect viral 
HCV RNA. The NATs are usually applied to screen blood donations and confirm 
viremia (Ferreira-Gonzalez and Shiffman, 2004, Morishima and Gretch, 1999). 
If the patient cannot afford RNA PCR detection, HCV core antigen detection also 
can be used instead of RNA PCR (EASL, 2017).The suspected acute hepatitis C or 
immunocompromised patients can apply HCV RNA testing as the initial evaluation. 
The HCV RNA sensitive molecular method should be used if anti-HCV antibodies are 
detectable. HCV antibody positive patients should be retested confirmed by HCV 
PCR (EASL, 2017). 
 
1.6.  Treatment of HCV 
1.6.1.  The previous HCV treatment with interferon and ribavirin 
Since 1998, the combination of ribavirin and interferon alfa was approved by the 
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FDA (U.S. Food and Drug Administration) for clinical application of hepatitis C 
infection. From 2001, The HCV treatment with Peg-IFN-α (Peg-interferon α-2a) and 
Ribavirin. In these previous treatments, the treatment duration was for 24 to 48 weeks, 
and the virologic cure rate was about 50% (Feld and Hoofnagle, 2005). The 
mechanisms of IFN-α and ribavirin include T helper type 1 immune responses, induce 
IFN-stimulated genes (ISGs),  inhibit inosine monophosphate dehydrogenase (Feld 
and Hoofnagle, 2005). This previous treatment was common with severe side effects, 
including flu-like symptoms, autoimmune diseases, neuropsychiatric symptoms, and 
hemolytic anemia (Manns et al., 2006).  Among younger patients and females, the 
response rates were higher. Those patients infected with genotype 2 or 3 could be 
treated more successfully than compared to genotype 1.                                        
 
1.6.2.  The goals and endpoints of HCV treatment 
The endpoints of HCV treatment is that HCV RNA cannot be detected at 12 and 
24 weeks after treatment, that is, Sustained virologic response SVR12 and SVR24 
were negative, and the lower limit of RNA PCR detection was less than 15 IU/ml 
(Martinot‐Peignoux et al., 2010). The goal of treatment is to cure HCV infection and 
prevent the HCV-related liver complications, such as fibrosis, cirrhosis, 
decompensation of cirrhosis, hepatic necroinflammation, HCC (EASL, 2017). 
 
  1.6.3.  The development of direct-acting antivirals (DAAs) 
The development of direct-acting antivirals (DAA) was based on the research of 
HCV virus structure, intended to inhibit HCV protease, such as NS3 protease, NS5A 
protein, NS5B polymerase, which play critical roles in the viral replication process 
(Pawlotsky, 2014). The first concept of HCV protease inhibitor was proposed in 2002, 
this is a turning point in HCV drug discovery (Lamarre et al., 2003). Since 2014, 
Several direct-acting antivirals (DAA) have been developed and approved for clinical 
applications in many countries. These compounds are principally targeted at the 
non-structural proteins and NS3-4 protease, the NS5A protein and the 
RNA-dependent polymerase and NS5B. These new viral inhibitors are very potent 
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and effective for all HCV genotypes. The application of these drugs has tremendously 
improved HCV cure rates, which now exceed clearly 90% in the tested patient 
population groups. 
The clinical results of the new IFN-free DAAs treatment were significantly better 
than the previous treatment proposal with IFN. The treatment duration of direct-acting 
antivirals is much shorter, the viral load quickly drops to negative within 8 weeks or 
12 weeks. In addition, there are fewer side effects compared with previous treatment 
proposals (Asselah et al., 2016). 
 
 
Fig. 3.  Direct‐acting antivirals (DAAs) for HCV treatment (Asselah et al., 2016)  
 
1.7.  HCV DAAs drugs approved in Europe in 2016  
The HCV DAAs drugs available in European countries in 2016 include 
sofosbuvir; sofosbuvir and ledipasvir (Harvoni); sofosbuvir and velpatasvir (Epclusa); 
grazoprevir and elbasvir (Zepatier); daclatasvir; simeprevir; ribavirin etc. The 
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presentation and posology of these drugs shown in the table 1 (EASL, 2017).  
 
 
Table 1.  Approved HCV DAAs in Europe in 2016 (EASL, 2017) 
 
 
Sofosbuvir 
 
The dose of sofosbuvir is 400 mg per tablet, one tablet once daily at morning. 
The toleration of sofosbuvir is over 12 to 24 weeks. The main excretion of the drug is 
by renal (80%). The common side effects of sofosbuvir combines with ribavirin were 
fatigue and headache (>20%). Contraindications of drug-drug interactions include: 
P-gh inducers (rifampin, phenytoin, carbamazepine, St. john’s wort), rifapentine, 
modafinil, rifabutin, anti-arrhythmic (amiodarone) (EASL, 2017). 
 
Sofosbuvir and ledipasvir (Harvoni®) 
 
The product name of sofosbuvir and ledipasvir combination is Harvoni®. The 
single tablet combines 400 mg sofosbuvir and 90 mg ledipasvir. One tablet once daily 
at morning. The excretion route of these two components are different, the main 
excretion of the sofosbuvir is by renal, but the major route of ledipasvir is biliary 
excretion. The common side effects of sofosbuvir and ledipasvir combination were 
fatigue and headache. Contraindications of drug-drug interactions include: P-gp 
substrates (dabigatran, digoxin), amlodipine, aliskiren, carvedilol, buprenorphine, 
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cyclosporine, amiodarone, rosuvastatin, tenofovir, tenofovir alafenamide (TAF). 
Especially need to be careful about amiodarone which can cause a serious risk or even 
fatal asystole or bradycardia (EASL, 2017). 
 
Sofosbuvir and velpatasvir (Epclusa®) 
 
The product name of sofosbuvir and velpatasvir combination is Epclusa®. The 
single tablet combines 400 mg sofosbuvir and 100 mg velpatasvir. One tablet once 
daily at morning. The excretion route of these two components are different, the main 
excretion of the sofosbuvir is by renal, but the major route of velpatasvir is biliary 
excretion. The common side effects of sofosbuvir and velpatasvir combination were 
fatigue, headache and nausea. Contraindications of drug-drug interactions include 
P-gp or CYP inducers (rifabutin, rifampicin, Phenobarbital, carbamazepine, phenytoin, 
St John's wort), modaifnil, proton pump inhibitor; efavirenz, nevirapine and etravirine 
in HCV-HIV coinfection patients (EASL, 2017). 
 
 Grazoprevir and elbasvir (Zepatier®) 
 
The product name of grazoprevir and elbasvir combination is Zepatier ®. The 
single tablet combines 100 mg grazoprevir and 50 mg elbasvir. One tablet once daily 
at morning. The main route of excretion is faecal and biliary. The common side effects 
of grazoprevir and elbasvir combination were fatigue and headache. Contraindications 
of drug-drug interactions include CYP3A or P-gp inhibitors which decrease plasma 
exposure of drugs, such as azole antifungals, boosted protease inhibitors, etravirine, 
efavirenz, phenytoin, bosentan, carbamazepine, St John's wort, modafinil, etc.(EASL, 
2017). 
 
Daclatasvir 
 
The dose of daclatasvir is 60 mg or 30 mg per tablet, one tablet once daily. The 
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main excretion of the drug is by faeces. The common side effects of daclatasvir were 
fatigue, headache and nausea. Contraindications of drug-drug interactions include 
P-gh and CYP3A4 inducers, such as antimycobacterial (rifapentine, rifampicin, 
rifabutin), anticonvulsants (carbamazepine, oxcarbazepine, phenytoin, phenobarbital), 
St John's wort and systemic dexamethasone etc. (EASL, 2017).  
 
Simeprevir 
 
The dose of simeprevir is 150 mg per tablet, one tablet once daily. Simeprevir 
widely bound to albumin in plasma proteins (>99.9%). The main excretion of the 
simeprevir is by biliary. The common side effects of simeprevir are pruritus, rash and 
nausea. Contraindications of drug-drug interactions include CYP3A4 inducers, 
antibiotics (clarithromycin, erythromycin, telithromycin), anticonvulsants 
(oxcarbazepine, carbamazepine, phenytoin, phenobarbital), antifungals (ketoconazole, 
fluconazole, itraconazole, voriconazole), antimycobacterial (rifabutin, rifapentine, 
rifampin), St John's wort, dexamethasone, cisapride et (EASL, 2017). 
 
1.8.  The treatment regimens for different genotype 
 
 
Table 2.  Treatment regimens recommendation for each HCV genotype  
(EASL, 2017) 
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The treatment proposal for each genotype of chronic hepatitis C patients 
according to European Association for the study of the liver shown in the table 3 
(EASL, 2017). 
 
Genotype Treatment options 
Genotype 1 1  Sofosbuvir and ledipasvir 
2  Sofosbuvir and velpatasvir 
3  Ritonavir boosted partitaprevir, ombitasvir and 
dasabuvir 
4  Greazoprevir and elbasvir 
5  Sofosbuvir and daclatasvir 
Genotype 2 1  Sofosbuvir and velpatasvir  
2  Sofosbuvir and daclatasvir 
Genotype 3 1  Sofosbuvir and velpatasvir 
2  Sofosbuvir and daclatasvir 
Genotype 4 1  Sofosbuvir and ledipasvir 
2  Sofosbuvir and velpatasvir 
3  Ombitasvir, paritaprevir and ritonavir 
4  Grazoprevir and elbasvir 
5  Sofosbuvir and daclatasvir 
6  Sofosbuvir and simeprevir 
Genotype 5 
Genotype 6 
1  Sofosbuvir and ledipasvir 
2  Sofosbuvir and velpatasvir 
3  Sofosbuvir and daclatasvir 
Table 3.  Treatment propotion for different genotype of hepatitis C patients 
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1.9.  Treatment regimens used in this study 
 
Abbreviation 
of regimen 
Full name 
(Components) 
Genotype Inhibitor 
SOF Sofosbuvir  1,  
2, 3, 4, 5, 6 
NS5B 
Harvoni Sofosbuvir  
Ledipasvir  
1,  
4, 5, 6 
NS5B 
NS5A 
SOF DAC Sofosbuvir 
Daclatasvir  
 
3 
NS5B 
NS5A 
SOF SMP Sofosbuvir 
Simeprevir  
 
HCV 1, 4  HIV 
NS5B 
NS3/4A 
Exviera+Viekirax Exviera  
Viekirax 
 
1b, 4 
NS5A， 
NS3/4A 
Epclusa Sofosbuvir 
Velpatasvir  
2, 3  
NS5A 
Zepatier Elbasvir  
Grazoprevir 
1, 4  
NS5A 
Table 4.  Treatment regimens used in this study 
 
1.10.  Summary of introduction 
There are approximately 185 million HCV infected people all over the world. A 
serious problem of HCV infection is the high chronicity rate of about 80% 
HCV-infected patients may develop liver cirrhosis or hepatocellular carcinoma. The 
HCV standard therapy with interferon and ribavirin was used since1990s, the success 
rate of this treatment was only about 50%, and it was HCV genotype dependent. This 
changed significantly since the direct-acting antivirals (DAAs) became available from 
2014 onwards. The success rate is much higher and can be achieved in a very short 
time. 
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2.  Materials and Methods 
 
2.1.  Patient population and data collection 
A total of 446 hepatitis C patients were treated with the direct acting antivirals 
(DAA) in the Department of Internal Medicine Ⅰ, University Hospital Tuebingen, in 
the period from January 2014 to 31 April 2017. Nine patients had to be deleted due to 
incomplete data. The final 437 patients with hepatitis C were included in the statistical 
study analysis. The data of 437 patients were taken from the Institute of Medical 
Virology University clinic of Tuebingen. The virological database of SwissLab 
program was used. All data of the patients were tabulated and categorized in 
Microsoft Excel databases. 
This retrospective observational analysis approved by the institutional review 
board of the Medical Faculty of the University of Tuebingen. The informed consent 
was exempted because of anonymous assessment of medical records. 
 
2.2.  Characteristics of study cohort patients 
The total number of patients is 437, consists of 265 males and 172 females. 
Patients age range from 19 to 87 years old, the average age is 52.6±12.9 (Mean ± SD). 
The Genotype of the patients include genotype 1a (134, 30.66%), genotype 1b (173, 
39.59%), genotype 1 unclassified (3, 0.69%), genotype 2a/b (12, 2.75%), genotype 
3a/b (89, 20.37%), genotype 4 (21, 4.81%), genotype 5 (2, 0.46%), 6 (3, 0.69%).  
 
2.3.  Special patients population 
Special patients population include patients with liver cirrhosis (123, 28.15%), 
liver transplantation (22, 5.03%), nephrectomy (6, 1.38%), pre-treated (212, 48.51%), 
coinfeciton with HIV (6, 1.37%), coinfeciton with HBV (2, 0.46%), relapse (15, 
3.43%), patients ≥ 60 yr (119, 27.23%), patients ≥ 80 yr (6, 1.37%). The clinical 
characteristics of our cohort are presented in table 5,6.  
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Patients Characteristics n     N=437 Proportion 
Gender  
 
Male 
Female 
Total 
n 
 
265  
172   
437   
% 
 
60.6% 
39.4% 
 
Age   
 
Mean ± SD   
Min - Max 
Patients ≥ 60 yr 
Patients ≥ 80 yr 
n 
 
52.6 ± 12.9 
19 - 87 
119  
6  
% 
 
 
 
27.23% 
1.37% 
Genotype 
 
1a 
1b 
1 unclassified 
2a/b 
3a/b 
4 
5 
6 
n 
 
134  
173  
3    
12   
89   
21   
2    
3    
 
% 
 
30.66% 
39.59% 
0.69% 
2.75% 
20.37% 
4.81% 
0.46% 
0.69% 
 
Table 5.  Characteristics of study cohort patients 
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Special patients Number Proportion 
Liver cirrhosis 123   28.15% 
Liver transplantation 22  5.03% 
Nephrectomy 6   1.38% 
Pre-treated 212  48.51% 
Replapse 15 3.43% 
Coinfeciton HIV 6  1.37% 
Coinfeciton HBV 2 0.46% 
Table 6.  Special patients population 
 
2.4.  Treatment regimens 
All 437 patients were treated with direct-acting antivirals (DAAs) at Department 
of Internal Medicine, University Hospital Tübingen. The treatment regiments include 
SOF (68, 15.56%), SOF/DAC (106, 24.26%), SOF/SMP (34, 7.78%), SOF/LDV 
(Harvoni) (160, 36.61%), Exviera/Viekirax (49, 11.21%), SOF/VEL (Epclusa) (16, 
3.66%), GZR/EBR (Zepatier) (4, 0.92%). The proportions of different treatment 
regimens are shown in Table 7.  
 
Treatment regimens Number Proportion 
SOF 68  15.56% 
SOF/DAC 106  24.26% 
SOF/SMP 34  7.78% 
SOF/LDV (Harvoni) 160 36.61% 
Exviera/Viekirax 49  11.21% 
SOF/VEL (Epclusa) 16   3.66% 
GZR/EBR (Zepatier) 4   0.92% 
Table 7.  Distribution of Treatment regimens 
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Abbreviation 
name 
Full name  
 
Product name Pharmaceutical 
company 
Country 
SOF Sofosbuvir  SOVALDI® Gilead Sciences, 
Inc. 
America 
 
SOF/LDV 
(Harvoni) 
Sofosbuvir 
Ledipasvir 
HARVONI® Gilead Sciences, 
Inc. 
America 
 
SOF/DAC Sofosbuvir  
Daclatasvir  
SOVALDI® 
DAKLINZA™ 
Gilead Sciences  America 
 
SOF/SMP Sofosbuvir 
Simeprevir  
SOVALDI®  
OLYSIO® 
Gilead Sciences,  
Medivir AB 
Janssen 
Pharmaceutica 
America 
Swedish 
Belgium 
Exviera/ 
Viekirax 
Exviera  
Viekirax 
EXVIERA® 
VIEKIRAX® 
AbbVie 
 
Switzerland 
SOF/VEL 
(Epclusa) 
Sofosbuvir  
Velpatasvir  
EPCLUSA® Gilead Sciences, 
Inc. 
America 
 
GZR/EBR 
(Zepatier) 
Grazoprevir 
Elbasvir 
ZEPATIER® Merck & Co, Inc 
 
America 
 
Table 8.  DAAs treatment regiments components and manufacturer 
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Drugs 
Abbreviation 
Component and dosage Posology 
 
SOF 
 
Sofosbuvir  400mg 
 
once daily 
LDV/SOF  
(Harvoni) 
Single tablet containing: 
Sofosbuvir  400mg 
Ledipasvir  90mg 
 
 
once daily 
SOF/DAC Sofosbuvir  400mg 
Daclatasvir  60mg 
 
once daily 
SOF/SMP Sofosbuvir  400mg 
Simeprevir  150mg 
 
once daily 
Exviera/Viekirax Exviera  250 mg 
Viekirax  12.5/50 /75 mg 
 
once daily 
SOF/VEL 
(Epclusa) 
Single tablet containing: 
Sofosbuvir  400 mg  
Velpatasvir  100 mg 
 
once daily 
GZR/EBR 
(Zepatier) 
Single tablet containing: 
Grazoprevir  100mg 
Elbasvir     50mg 
 
 
once daily 
Table 9.  Treatment regiments dose and duration (EASL, 2017) 
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2.5.  Parameters and observation periods 
 
PCR tests and recording periods: 
Real-time PCR was used to detect the hepatitis C viral load from peripheral blood 
of the patients, The PCR (Polymerase chain reaction) in cell culture was detected 
quantitatively.  
For virological analyses, Roche CobasAmpliprep/Roche Cobas TaqMan (Roche 
Diagnostics GmbH, Mannheim, Germany) was used. The lower limit of quantification 
(LLOQ) is 15 IU/mL. 
HCV RNA levels in serum or plasma are typically measured at 0 (Baseline viral 
load), 2, 4 weeks (rapid virologic response, RVR); 8, and 12 weeks (early virologic 
response: EVR) of therapy; end of treatment (8, 12, or 24 weeks depending on HCV 
genotype and treatment response); and 12, 24, 48 weeks post-treatment (sustained 
virologic response: SVR12, SVR12, SVR48). 
 
2.6.  Interpretation of reference values  
 
The quantitative result expressed in IU/mL or log IU/mL, which means the degree 
of active HCV viral replication in the blood. The CobasTaqMan has result values 
range from 15 to 100 million IU/mL (1.18 - 8.00 log IU/mL) for quantification of 
hepatitis C virus. 
 
The result value of <15 IU/mL indicates that HCV RNA is detected, but this level 
of  HCV RNA cannot be quantified accurately. 
 
The result value of >100 million IU/mL (>8.00 log IU/mL) indicates the active 
HCV viral replication. The viral load quantification cannot be quantified accurately if 
the HCV RNA level above this upper limit. 
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2.7.  Laboratory and Clinical parameters 
The following qualitative parameters were collected: 
 
1  Biometric data: 
• Age 
• Gender 
• Genotype of HCV 
• Main and secondary diagnoses 
 
2  Clinical data 
• Liver cirrhosis 
• Liver transplantation 
• Nephrectomy 
• Pre-treated 
• Relapse 
• Coinfection with HIV 
• Coinfection with HBV 
• Start time of treatment  
• End time of treatment  
• Duration of treatment  
• Completion of treatment 
 
3  Laboratory parameters: 
• Viral load (HCV RNA copies/ml of blood) 
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• ALT (Alanine transaminase) (U/L) 
• Hemoglobin (mg/dl)  
• PLT (Platelets) (109/L) 
• Bilirubin (μmol/L) 
• Creatinine (mg/dl) 
• WBC (leukocytes) (109/L) 
4  Viral load measuring time 
• PCR 0 (Baseline viral load) 
• PCR 2 (2 weeks during treatment) 
• PCR 4 (4 weeks during treatment) 
• PCR 8 (8 weeks during treatment) 
• PCR 12 (12 weeks during treatment) 
• PCR 24 (24 weeks during treatment) 
• SVR (Sustained virologic response) 
• SVR 12 (12 weeks post treatment)   
• SVR 24 (24 weeks post treatment) 
• SVR 48 (48 weeks post treatment) 
5  Comorbidity and complications: 
• Liver cirrhosis 
• Liver failure 
• Liver transplantation 
• Liver cancer 
• Death during or after treatment 
23 
 
 
2.8.  Statistical analysis 
 
437 patients were included for statistical analysis. All collected data and 
parameters were stored in a database of the Microsoft Office Excel 2010®.  The data 
were statistically analyzed using JMP13.0 software. Multiple of statistical analysis 
methods were used in this study, including student's t-test, normal distribution test, 
distribution analysis, bivariate analysis, one-way analysis, logistic fit analysis and 
contingency analysis, etc. The SVR 12 rate, relapse patients, coinfection with HBV or 
HIV, and liver cirrhosis patients were enrolled in the multi-factor analysis. 
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3．Results 
 
3.1.  Characteristics of study cohort patients 
Patients characteristics  n,        %          N=437 
Gender  
Male 
Female 
 
265     (60.6%) 
172     (39.4%) 
Age   
Mean±SD   
(Min-Max) 
Patients ≥ 60 yr 
Patients ≥ 80 yr 
 
52.6±12.9 yr 
19 – 87  yr 
119     (27.23%) 
6       (1.37%) 
Table 10.  Characteristics of cohort hepatitis C patients 
 
3.1.1.  Gender 
The patient population consisted of 265 males and 172 females, and the 
proportion of male patients (60.6%) was obviously more than that of female patients 
(39.4%), with statistically significant differences (Fig.4).  
 
 
Fig. 4.  Gender proportion of 437 hepatitis C patients 
0
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3.1.2.  Age 
Patients age range from 19 to 87 years old, the average age is 52.59±12.98 
yr(Mean±SD). The frequency distribution pattern of age is shown in Fig，50-60 age 
accounted for the largest proportion, followed by the 60-65 age group and 45-50 age 
group, 15-25 age group and 80-90 age group accounted for the smallest proportion. 
 
 
Fig. 5.  Age distribution of hepatitis C patients 
 
 
3.1.3.  Genotypes of HCV 
The Genotype of the patients include genotype 1a (134, 30.66%), genotype 1b 
(173, 39.59%), genotype 1 unclassified (3, 0.69%), genotype 2a/b (12, 2.75%), 
genotype 3a/b (89, 20.37%), genotype 4 (21, 4.81%), genotype 5 (2,0.46%), 6 (3, 
0.69%). 
It is clear that the proportion of patients with genotype 1a/b is the largest group, 
followed by genotype 3 group, genotype 5 and genotype 6, the lowest number of 
patients. 
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Genotype N       % 
1a 
1b 
1 unclassified 
2a/b 
3a/b 
4 
5 
6 
134    （30.66%） 
173    （39.59%） 
3      （0.69%） 
12     （2.75%） 
89     （20.37%） 
21    （4.81%） 
2      （0.46%） 
3      （0.69%） 
Table 11.  The proportion of different genotypes of HCV 
 
 
3.1.4.  Treatment duration 
There were three different types of treatment duration: 8 weeks（48, 10.98%）, 12 
weeks（313, 71.62%）, 24 weeks (75, 17.16%). Most of Hepatitis C patients had a 
12-weeks duration of treatment (Fig. 12).  
 
Treatment duration n          %      N=437 
24 weeks 
12 weeks 
8 weeks 
75  
313  
48 
17.16% 
71.62% 
10.98% 
Table 12.  The proportion of treatment duration 
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Fig. 6.  Treatment duration of hepatitis C patients 
 
 
 
Fig. 7.  Treatment duration of with/without liver cirrhosis patients 
 
 
313 
71.62% 
75 
17.16%  48 
10.98% 
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3.1.5.  Treatment regimens 
 
All 437 patients were treated with direct-acting antivirals (DAAs) in the Department 
of Internal MedicineⅠ, University Hospital Tuebingen. The treatment regimens include 
SOF (68, 15.56%), SOF/DAC (106, 24.26%), SOF/SMP (34, 7.78%), LDV/SOF 
(Harvoni) (160, 36.61%), Exviera/Viekirax (160, 36.61%), SOF/VEL (Epclusa) (16, 
3.66%), GZR/EBR (Zepatier) (4, 0.92%). Among these treatment Regimens, the 
number of LDV/SOF (Harvoni)is the largest, followed by SOF/DAC, the least use is 
Epclusa and Zepatier. The proportions of different treatment regimens are shown in 
table 13 and figure 8. 
 
Treatment 
Regimens 
Full name  
(Component) 
n       Proportion  
N=437 
LDV/SOF 
(Harvoni) 
Sofosbuvir 
Ledipasvir 
160,   （36.61%） 
SOF/DAC Sofosbuvir  
Daclatasvir  
106,   （24.26%） 
SOF Sofosbuvir  68,    （15.56%） 
Exviera/Viekirax Exviera  
Viekirax 
49,    （11.21%） 
SOF/SMP Sofosbuvir 
Simeprevir  
34,    （7.78%） 
SOF/VEL 
(Epclusa) 
Sofosbuvir  
Velpatasvir  
16,   （3.66%） 
GZR/EBR 
(Zepatier) 
Elbasvir  
Grazoprevir  
4,    （0.92%）  
Table 13.  Treatment Regimens of 437 Hepatitis C patients 
 
29 
 
 
Fig. 8.  Treatment regimens of hepatitis C patients  
 
3.1.6.  Baseline clinical chemistry of the 437 hepatitis C patients 
 
Test Unit Mean Std Dev Min Max 
Hemoglobin (mg/dL) 14.43 5.26 5.2 115 
WBC (/dL) 8169.54 37169.08 655 766660 
PLT (1000/μL) 182.47 95.28 3 1085 
INR (INR) 1.08 0.25 0.9 4.4 
Creatinine (mg/dL) 0.82 0.62 0 6.8 
Bilirubin (mg/dL) 1.42 6.31 0.1 98 
ALT (IU/1) 82.97 62.01 14 465 
Table 14.  Baseline clinical chemistry of 437 hepatitis C patients 
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3.2.  Overall treatment outcome 
 437 Hepatitis C patients were treated with second-generation direct-acting 
antivirals (DAAs). All the 437 patients' viral load dropped to zero within 24 weeks 
during the treatment. Among them, 403 patients successfully with SVR12 HCV RNA 
negative; 15 patients relapsed; 2 patients died and one patients terminated, 16 patient 
(3.66%) lost to follow up after treatment. 
 
 
Treatment outcome 
 
Number 
SVR12 negative 403 
Relapse 15 
Death 2 
Lost to follow up 16 
Termination 1 
Total 437 
Table 15.  Overall treatment outcome of total 437 patients 
 
 
Fig. 9.  Overall treatment outcome of total 437 patients 
 
SVR12 negative
403
Relapse
15
Lost to follow up
16
Termination
1
Death
2
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3.3.  Analysis of SVR12 rate 
 
Overall SVR12 rates 
The overall SVR12 rate is 95.95%. 420/437 patients have finished the follow up 
after treatment and with SVR12 data available. 16/437 patients lost to follow up, and 
1/437 patient terminated although his viral load has dropped to negative during 
treatment. These 17/ 437 patient (16 lost to follow up and 1 termination) were 
excluded from the analysis of SVR12 rate because without data of SVR12. Total 
420/437 patients were involved in the analysis of SVR 12 rate. These 420 patients 
including SVR12 negative (403/420, 95.95%), relapse (15/420, 3.57%) and death 
(2/420, 0.47%).   
 
SVR12 rates of subgroups 
SVR12 rate for genotype were: 96.92% for GT1a, 95.78% for GT1b, 93.02% for 
GT3, 100% for GT1 unclassified, GT2, GT4, GT5 and GT6.  
SVR12 rate for treatment regiments were: 96.71% for Harvoni, 95.28% for 
SOF/DAC, 93.94% for SOF, 100% for Exviera/Viekirax, 91.18% for SOF/SMP, 100% 
for Epclusa, 100% for Zepatier.  
SVR12 rate for comorbidity and coinfection were: 90.76% for liver cirrhosis, 
90.91% for liver transplantation, 95.61% for pretreated. SVR12 rate 100% for 
coinfection with HIV, 50% for coinfection with HBV.  
SVR12 rate for gender: 94.53% for male, 98.17% for female.  
SVR12 rate for treatment duration: 95.96% for 8 weeks, 97.01% for 12 weeks, 
91.89% for 24 weeks. 
SVR12 rate for baseline viral load: The patients with high viral load (>800,000 
IU/mL) and very high viral load (>6,000,00 IU/mL) have higher SVR12 rate 
compared to the low viral load (<800,000 IU/mL). 
SVR12 rate statistical correlation with liver cirrhosis (P=0.0016*), liver 
transplantation (P=0.0166), coinfection with HBV (P=0.0004*), baseline PLT 
(P=0.0068*).  
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3.3.1.  Analysis SVR12 rate of genotype 
 
 
 
Fig. 10.  Analysis of SVR12 rate by genotype  
 
 
Count 
Row % SVR12 Relapse Death Total 
1 unclassified 3 100.00 
0 
0.00 
0 
0.00 3 
1a 126 96.92 
4 
3.08 
0 
0.00 130 
1b 159 95.78 
5 
3.01 
2 
1.20% 166 
2a/b 12 100.00 
0 
0.00 
0 
0.00 12 
3a/b 80 93.02 
6 
6.98 
0 
0.00 86 
4 18 100.00 
0 
0.00 
0 
0.00 18 
5 2 100.00 
0 
0.00 
0 
0.00 2 
6 3 100.00 
0 
0.00 
0 
0.00 3 
Total 403 15 2 420 
Table 16.  Analysis SVR 12 outcome by genotype 
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3.3.2.  Analysis SVR12 rate of treatment regimens 
 
 
Fig. 11.  Analysis SVR12 rate of treatment regimens 
 
 
Count 
Row % 
Negative Relapse Death Total 
Epclusa 14 
100.00 
0 
0.00 
0 
0.00 
14 
Exviera+Viekirax 46 
100.00 
0 
0.00 
0 
0.00 
46 
Harvoni 147 
96.71 
5 
3.29 
0 
0.00 
152 
SOF 62 
93.94 
4 
6.06 
0 
0.00 
66 
SOF DAC 101 
95.28 
5 
4.72 
0 
0.00 
106 
SOF SMP 31 
91.18 
1 
2.94 
2 
5.88 
34 
Zepatier 2 
100.00 
0 
0.00 
0 
0.00 
2 
Total 403 15 2 420 
Table 17.  Analysis SVR12 rate of treatment regimens 
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3.3.3.  Analysis treatment regimens for different genotypes 
 
3.3.3.1  Treatment regimens for GT1a 
 
Count 
Row % 
SVR12 
Negative Relapse Total 
Exviera+Viekirax 8 100.00 
0 
0.00 8 
Harvoni 78 98.73 
1 
1.27 79 
SOF 11 84.62 
2 
15.38 13 
SOF DAC 27 96.43 
1 
3.57 28 
SOF SMP 2 100.00 
0 
0.00 2 
Total 126 4 130 
Table 18.  Treatment regimens SVR12 rate of GT1a 
 
 
3.3.3.2  Treatment regimens for GT1b 
 
Count 
Row % 
SVR12 
Negative Relapse Death Total 
Epclusa 1 100.00 
0 
0.00 
0 
0.00 1 
Exviera+Viekirax 34 100.00 
0 
0.00 
0 
0.00 34 
Harvoni 61 95.31 
3 
4.69 
0 
0.00 64 
SOF 11 91.67 
1 
8.33 
0 
0.00 12 
SOF DAC 28 96.55 
1 
3.45 
0 
0.00 29 
SOF SMP 22 91.67 
0 
0.00 
2 
8.33 24 
Zepatier 2 100.00 
0 
0.00 
0 
0.00 2 
Total 159 5 2 166 
Table 19.  Treatment regimens SVR12 rate of GT1b 
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3.3.3.3  Treatment regimens for GT3 
 
Count 
Row % 
SVR12 
Negative Relapse Total 
Epclusa 11 100.00 
0 
0.00 11 
Exviera+Viekirax 2 100.00 
0 
0.00 2 
Harvoni 0 0.00 
1 
100.00 1 
SOF 25 96.15 
1 
3.85 26 
SOF DAC 41 93.18 
3 
6.82 44 
SOF SMP 1 50.00 
1 
50.00 2 
Total 80 6 86 
Table 20.  Treatment regimens SVR12 rate of GT3 
 
3.3.4.  Analysis SVR12 rate of gender 
 
Fig. 12.  Analysis SVR12 outcome by gender 
 
Count 
Row % 
Death Negative Relapse Total 
Female 0 
0.00 
161 
98.17 
3 
1.83 
164 
Male 2 
0.78 
242 
94.53 
12 
4.69 
256 
Total 2 403 15 420 
Table 21.  Analysis SVR12 outcome by gender 
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3.3.5.  Analysis SVR12 rate by with/without liver cirrhosis 
 
 
 
Fig. 13.  SVR 12 rate by with/without liver cirrhosis (P=0.0016*) 
 
 
 
 
Count 
Row % 
Negative Relapse Death Total 
Without 
Liver cirrhosis 
295 
98.01 
6 
1.99 
0 
0.00 
301 
 
Liver cirrhosis 
108 
90.76 
9 
7.56 
2 
1.68 
119 
Total 403 15 2 420 
 
Table 22.  SVR 12 rate by with/without liver cirrhosis (P=0.0016*) 
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3.3.6.  Analysis of SVR12 rate by with/without liver transplantation 
 
 
Fig. 14.  SVR 12 rate by with/without liver transplantation (P=0.0166*) 
 
 
 
 
Count 
Row % 
Negative Relapse Death Total 
Without  
Liver 
transplantation 
383 
96.23 
14 
3.52 
1 
0.25 
398 
Liver 
transplantation 
20 
90.91 
1 
4.55 
1 
4.55 
22 
Total 403 15 2 420 
Table 23.  SVR 12 rate by with/without liver transplantation (P=0.0166*) 
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3.3.7.  Analysis of SVR12 rate by baseline PLT (Platelets) 
 
 
Fig. 15.  Logistic fitting of SVR12 rate by baseline PLT (P=0.0068*)  
 
 
Fig. 16.  SVR12 rate by baseline PLT (P=0.0068*) 
 
Count 
Row % Negative Relapse Death Total 
PLT<100 65 89.04 
7 
9.59 
1 
1.37 73 
PLT>100 320 97.26 
8 
2.43 
1 
0.30 329 
Total 385 15 2 402 (18 patients no data) 
Table 24.  SVR12 rate by baseline PLT (P=0.0068*) 
Platelets
PLT<100 PLT>1000
25
50
75
100
125
150
175
200
225
250
275
300
325
350
SVR12
death
negative
relapse
9.59%
89.04%
2.43%
97.26%
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3.3.8.  Analysis of SVR12 rate by with/without pre-therapy 
 
 
 
 
Fig. 17.  SVR12 rate by with/without pre-therapy 
 
 
 
 
Count 
Row % Negative Relapse Death Total 
Without 
Pre-therapy 
207 
96.28 
8 
3.72 
0 
0.00 215 
With 
Pre-therapy 
196 
95.61 
7 
3.41 
2 
0.98 205 
Total 403 15 2 420 
Table 25.  SVR12 rate by with/without pre-therapy 
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3.3.9.  Analysis of SVR12 rate by treatment duration 
 
 
Fig. 18.  SVR12 rate of treatment duration 
 
 
 
 
Count 
Row % 
Negative Relapse Death Total 
8 weeks 43 
95.56 
2 
4.44 
0 
0.00 
45 
12 weeks 292 
97.01 
7 
2.33 
2 
0.66 
301 
24 weeks 68 
91.89 
6 
8.11 
0 
0.00 
74 
Total 403 15 2 420 
Table 26.  SVR12 rate of treatment duration 
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3.3.10.  Analysis of SVR12 outcome by Age  
 
 
Fig. 19.  SVR12 outcome by Age distribution 
 
 
 
 
 
Fig. 20.  Logistic fitting of SVR12 rate by age 
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Analysis of SVR12 outcome by Age>60 
 
 
 
Fig. 21.  Analysis SVR12 rate by age>60 
 
 
 
 
Count 
Row % 
Relapse SVR12  
Negative 
Death Total 
Age<60 14 
4.43 
301 
95.25 
1 
0.32 
329 
Age>60 1 
0.93 
107 
99.07 
1 
0.96 
108 
Total 15 403 2 420 
Table 27.  Analysis SVR12 rate by age>60 
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3.3.11  Analysis of SVR12 outcome by baseline viral load 
 
 
Fig. 22.  SVR12 rate by baseline viral load distribution 
 
 
 
 
Fig. 23.  SVR12 rate by high viral load 
 
 
 
44 
 
 
 
 
 
Count 
Row % 
SVR12  
Negative Relapse Death Total 
Baseline viral load 
>800,000 
270 
96.43 
9 
3.21 
1 
0.36 280 
Baseline viral load 
<800,000 
133 
95.00 
6 
4.29 
1 
0.71 140 
Total 403 15 2 420 
Table 28.  Analysis SVR12 rate by high viral load (>800,000 IU/mL) 
 
 
 
 
Count 
Row % 
SVR12  
Negative Relapse Death Total 
Baseline viral load 
>6,000,000 
62 
100.00 
0 
0.00 
0 
0.00 62 
Baseline viral load 
<6,000,000 
341 
95.25 
15 
4.19 
2 
0.56 358 
Total 403 15 2 420 
Table 29.  Analysis SVR12 rate by very high viral load (>6,000,000 IU/mL) 
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3.4.   Analysis of genotype 
 
3.4.1.  Analysis of treatment regimens by genotypes 
 
 
Fig. 24.  Analysis genotype by treatment regimens 
 
 
Count 
Row % 
1 
unclassified 1a 1b 2a/b 3a/b 4 5 6 Total 
Epclusa 0 0.00 
0 
0.00 
1 
6.25 
0 
0.00 
13 
81.25 
1 
6.25 
0 
0.00 
1 
6.25 16 
Exviera+Viekirax 0 0.00 
8 
16.33 
35 
71.43 
0 
0.00 
2 
4.08 
4 
8.16 
0 
0.00 
0 
0.00 49 
Harvoni 0 0.00 
82 
51.25 
68 
42.50 
0 
0.00 
1 
0.63 
6 
3.75 
2 
1.25 
1 
0.63 160 
SOF 0 0.00 
14 
20.59 
12 
17.65 
12 
17.65 
27 
39.71 
2 
2.94 
0 
0.00 
1 
1.47 68 
SOF DAC 3 2.83 
28 
26.42 
29 
27.36 
0 
0.00 
44 
41.51 
2 
1.89 
0 
0.00 
0 
0.00 106 
SOF SMP 0 0.00 
2 
5.88 
24 
70.59 
0 
0.00 
2 
5.88 
6 
17.65 
0 
0.00 
0 
0.00 34 
Zepatier 0 0.00 
0 
0.00 
4 
100.00 
0 
0.00 
0 
0.00 
0 
0.00 
0 
0.00 
0 
0.00 4 
Total 3 134 173 12 89 21 2 3 437 
Table 30.  Analysis of genotype by treatment regimens  
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3.4.2.  Analysis of genotype by gender 
 
 
Fig. 25.  Analysis of genotype by gender 
 
 
 
Count 
Row % 
1 
unclassified 
1a 1b 2a/b 3a/b 4 5 6 Total 
Female 2 
1.16 
39 
22.67 
91 
52.91 
6 
3.49 
28 
16.28 
3 
1.74 
2 
1.16 
1 
0.58 
172 
Male 1 
0.38 
95 
35.85 
82 
30.94 
6 
2.26 
61 
23.02 
18 
6.79 
0 
0.00 
2 
0.75 
265 
Total 3 134 173 12 89 21 2 3 437 
Table 31.  Analysis of genotype by gender 
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3.4.3.  Analysis of relapse by genotype 
 
 
Fig. 26.  Analysis of relapse by genotype 
 
 
 
Count 
Row % 
1 
unclassified 
 
1a 
 
1b 
 
2a/b 
 
3a/b 
 
4 
 
5 
 
6 
 
Total 
No 
relapse 
3 
0.71 
130 
30.81 
168 
39.81 
12 
2.84 
83 
19.67 
21 
4.98 
2 
0.47 
3 
0.71 
422 
 
Relapse 
0 
0.00 
4 
26.67 
5 
33.33 
0 
0.00 
6 
40.00 
0 
0.00 
0 
0.00 
0 
0.00 
15 
Total 3 134 173 12 89 21 2 3 437 
Table 32.  Analysis of relapse by genotype 
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3.4.4.  Analysis of liver cirrhosis by genotype 
 
 
Fig. 27.  Analysis of liver cirrhosis by genotype 
 
 
3.4.5.  Analysis of genotype by treatment duration 
 
 
Fig. 28.  Analysis of genotype by treatment duration 
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3.5.   Viral load 
 
3.5.1.  Baseline viral load 
 
The baseline viral load ranges of 437 patients range from 672 to 70,700,000 
IU/mL. The distribution of baseline viral load result shows the majority of patients are 
in the range from 1,000,000 to 10,000,000 IU/m, followed by the range from 100,000 
to 1,000,000 IU/mL. Few patients with viral load <100,000 IU/mL or >10,000,000 
IU/mL. 
 
3.5.2.  High viral load vs. Low viral load 
 
The baseline viral load is divided into three levels, include low viral load, high 
viral load and very high rival load. High viral load is defined as PCR ≥800,000 IU/ml 
or ≥2.000.000 IU/mL, and ≥6.000.000 IU/mL is considered to very high viral load. 
Low viral load is considered to <800,000 IU/ml.  
 
    In this study, There are 145 (33.18%) patients with low viral load (<800.000 
IU/mL). Most of the patients 292 (67.73%) with high viral load ≥800.000 IU/mL. A 
small part of the patient with the very high viral load: 99 (22.65%) ≥6.000.000 IU/mL; 
4 (0.92%) ≥25.000.000 IU/mL. 
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Fig. 29.  Frequency distribution of baseline viral load 
 
 
 
 
Baseline Viral load Number  Proporiton 
<800.000 IU/mL   Low viral load 145     (33.18%) 
≥800.000 IU/mL   High viral load 292     (67.73%) 
≥6.000.000 IU/mL  Very high viral load 99      (22.65%) 
≥25.000.000 IU/mL  Very high viral load 4       (0.92%) 
Table 33.  High viral load vs. Low viral load 
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Fig. 30.  High viral load vs. Low viral load of hepatitis C patient’s proportion 
 
 
 
Baseline Viral load 
Mean 3109403.73 
Min 672 
Max 70.700.000 
Std Dev 5470164.4 
Upper 95% Mean 3624889.5 
Lower 95% Mean 2593918 
75.0%  Quartile 3870000 
50.0%  Median 1500000 
25.0%  Quartile 478000 
Table 34.  Analysis of Baseline Viral load 
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3.5.3.   Min time of viral load drop to zero during treatment 
Analysis of the PCR 0 min time showed that most patients’ viral load drop to 
zero at 4weeks (220, 50.69%), followed by 12 weeks (144, 33.18%), and even some 
patients in the second week, the viral load decline to zero with rapid speed. Total 434 
patients were included in the analysis because there are 3 patients’ viral load’ data 
were incomplete during treatment. 
 
 
Fig. 31.  Min time of viral load drop to 0 during treatment 
 
 
3.5.4.  PCR-negative/positive ratio at different times 
For the analysis of the PCR negative / positive ratios at different times, the 
results showed that the viral load of most patients in the fourth week decreased to zero. 
The viral load of some patients dropped to zero in the second week. From the fourth 
week to the eighth week, the majority of patients PCR have turned to negative. 
Because the patient did not perform PCR testing every week, most patients were 
tested in the fourth week from the beginning of the treatment, so most of the data in 
the second week was unknown. 
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Fig. 32.  Viral load negative/positive percentage at different time 
 
3.5.5.   Viral load changed with time 
From the graph of PCR trend with time, it can be observed that most patients' 
viral load were reduced to zero in the fourth week. 
Patients with a very high viral load of more than 25.000.000 IU/mL have 
decreased at a faster rate compared to other patients with viral load less than 
25.000.000 IU/mL. Patients with very high viral load ≥25.000.000 IU/mL were 
dropped rapidly to zero within the fourth week. Even the patients with viral loads 
greater than 50.000.000 IU/mL and more than 70.000.000 IU/mL also decrease 
rapidly to 0 in the fourth week. On the other hand, Some patients with viral load 
levels below 25.000.000 IU/mL have slower PCR rates, PCR of viral load were 
reduced to 0 at week 12 or even 24 weeks. 
The changes in viral load changing with time were analyzed by using Bivariate 
Fit analysis, show in the fitting curve of figure 33.   
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Viral load changing with time 
 
Fig. 33.  Viral load changing with Time (437 patients) 
 
 
 
Fig. 34.  Viral load changing with Time (437 patients) 
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3.5.6.   Patients with very high viral load 
 
There are four patients with the very high viral load > 25.000.000 IU/mL, The 
Patient Nr. 042 with the highest viral load PCR>70.000.000 IU/mL shows decreased 
rapidly, in 4weeks fell to <800.000 IU/mL, and PCR drop to zero in 8 weeks. The 
other four patients with viral load > 25.000.000 IU/mL (Patient Nr. 042 Baseline Viral 
load 70.700.000 IU/mL; Patient Nr. 211 Baseline Viral load 48.800.000 IU/mL; 
Patient Nr. 128 Baseline Viral load 34.600.000 IU/mL; Patient Nr. 173 Baseline Viral 
load 27.200.000 IU/mL), their viral load dropped very quickly to zero within 4 weeks. 
The changes in viral load changing with time were analyzed by using Bivariate Fit 
analysis, shown in figure 35.   
 
 
 
Fig. 35.  Very high viral load changing with time (PCR >25,000,000 ) 
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Fig. 36.  Patient Nr. 042  Very high viral load 70,700,000  (PCR>60,000,000 ) 
 
 
 
 
Fig. 37.  Patient Nr. 211  Very high viral load 48,800,000  (PCR >25,000,000 ) 
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Fig. 38.  Patient Nr. 128  Very high viral load 34,600,000 (PCR >25,000,000 ) 
 
 
 
 
Fig. 39.  Patient Nr. 173 Very high viral load 27,200,000  (PCR >25,000,000 ) 
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3.6.   Relapse in Hepatitis C patients 
 
3.6.1.  General characters of the relapse patients 
There are 15 relapse patients in the total 437 hepatitis C patients. It can be 
observed from these relapse patients that: the gender ratio shows male patients (12/15, 
80%) obviously more than female patients (3/15, 20%), with significant statistical 
differences (P<0.01).  
The age of all relapse patients range from 38 (Min) to 63 (Max), the average age 
was 50.13±6.28 (MV±SD). 
The treatment duration includes 24 weeks, 12 weeks and 8 weeks. There are six 
relapsed patients with 24 weeks treatment duration (6/15, 40%), seven patients with 
12 weeks treatment duration (7/15, 46.67%), and two patients with 8 weeks duration 
(2/15, 13.33%).  
The relapsed patients had three kinds of genotypes: 1a, 1b, 3a/b. There are 3 
patients with genotype 1a (4/15, 26.67%), 5 patients with 1b (5/15, 33.33%), and 6 
patients with 3a/b (6/15, 40%).  
The treatment regimens included SOF (4/15, 26.67%), SOF DAC (5/15, 31.25%), 
Harvoni (5/15, 33.33%), SOF SMP (1/15, 6.67%). 
The number of special patients with liver cirrhosis is 9 (60%), with significant 
statistical differences (P<0.01*). There are no patients with liver transplantation and 
nephrectomy in the relapse patients. 
After treatment, there are 8 (53.33%) relapse patients’ SVR12 with high viral 
load (> 6 Mio IU/mL) vs. 7 (46.67%) patients with low viral load (< 6 Mio IU/mL); 2 
(13.33%) patients’ SVR24 with high viral load (> 6 Mio IU/mL) vs 13 (86.67%) 
patients with low viral load (< 6 Mio IU/mL); and 5 (33.33%) patients’ SVR48 with 
high viral load (> 6 Mio IU/mL) vs. 10 (66.67%) patients with low viral load (< 6 Mio 
IU/mL).  
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Relapse patients  n,    %          N=15 
Gender  
Male 
Female 
 
12  (80%) 
3   (20%) 
Age   
Mean±SD  (Min - Max) 
>60 yr 
 
50.13±6.28  (38 - 63) 
1   (6.67%) 
Treatment duration 
24 weeks 
12 weeks 
8 weeks 
 
6   (40%), 
7   (46.67%), 
2   (13.33%).  
Genotype 
1a 
1b 
3a/b 
 
4  （26.67%） 
5  （33.33%） 
6  （40%） 
Treatment regimens 
SOF 
SOF DAC 
Harvoni 
SOF SMP 
 
4   (26.67%) 
5   (31.25%) 
5   (33.33%) 
1   (6.67%) 
Special patients 
Liver cirrhosis 
Liver transplantation 
Nephrectomy 
 
9   (60%)   P<0.01* 
0 
0 
Coinfection 
HBV 
HIV 
 
1   (6.67%) 
0 
60 
 
Pre-therapy 
 
With 
without 
n,  %          N=15 
 
6   (40%) 
9   (60%) 
Baseline platelet count 
Low platelets  (≤100/nL) 
 
7   (46.67%) 
Baseline viral load 
<800.000 IU/mL   Low viral load 
≥800.000 IU/mL   High viral load 
≥6.000.000 IU/mL  Very high viral load 
 
6   (40%) 
9   (60%) 
0 
SVR 12  
≥800.000 IU/mL   High viral load 
≥6.000.000 IU/mL  Very high viral load 
 
8   
2   
SVR 24 
≥800.000 IU/mL   High viral load 
≥6.000.000 IU/mL  Very high viral load 
 
10   
2   
SVR 48 
≥800.000 IU/mL   High viral load 
≥6.000.000 IU/mL  Very high viral load 
 
11   
0 
61 
 
Baseline clinical chemistry 
 
ALT          (IU/1) 
Platelets       (1000/μL) 
WBC         ( /μL) 
Hemoglobin    (g/dL) 
Creatinine     (mg/dL) 
Bilirubin      (mg/dL) 
INR          (INR) 
Mean±SD  (Min - Max) 
 
74.21±44.96    (21-191) 
34.87±87.09    (43-287) 
5010±1817.43   (1840-8090) 
13.53±2.96     (8.7-18) 
13.53±2.96     (8.7-18) 
1.09±0.64      (0.4-2.3) 
1.14±0.12      (1-1.3) 
Table 35.  Characteristics of relapse patients  
 
 
 
3.6.2.  Viral load of relapse patients 
From the table of viral load changing during treatment and after treatment of 
relapse patients, 15 patients had relapsed of the 437 patients, and the viral load of 
these patients had dropped to zero with PCR DNA negative during treatment (within 
24 weeks), but during follow-up the viral load was found increased again after 
treatment.  
The results show most of the 15 relapsed patients’ viral load dropped to zero 
within 12 weeks, and most of them (11/15, 73.33%) the viral load changed rapidly to 
negative (zero or less than 15) within 4 weeks. From the 8 weeks to 24 weeks, these 
patients kept negative, but after treatment, the sustained virological response (SVR12, 
SVR24 and SVR48) increased a lot, some have even increased several times 
compared to the baseline viral load. The patient P213 with very low value at baseline 
viral load (8430) increased 70 times during SVR12 (590000) and 150 times during 
SVR24 (1280000).  
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Patient 
Nr. 
Baseline 
Viral 
load 
2 
weeks 
4 
weeks 
8 
weeks 
12 
weeks 
18 
weeks 
24 
weeks 
SVR  
12 
SVR  
24 
SVR  
48 
P030 4890000 6130 195 0 0 0 0 13900000 782000 69100 
P070 105000 0 0 0 163000 839000 
P084 1380000 175 <15 0 0 0 1200000 640000 1050000 
P213 8430 <15 0 0 0 590000 1280000 170000 
P214 1740000 0 0 0 0 0 110000 
P289 3160000 135 0 0 0 0 0 2530000 1810000 2760 
P058 10300 <15 0 2190 152000 
P091 3390000 <15 0 425000 1120000 1490000 
P094 321000 <15 0 0 2670000 955000 2570000 
P121 4910000 16 0 17900000 16900000 
P207 408000 <15 0 0 768000 0 
P375 862000 0 0 97600 197000 
P421 3030000 <15 0 0 4490000 8960000 5960000 
P237 469000 0 0 1690000 1110000 1870000 
P407 2180000 0 0 1270000 
Table 36.  Viral load and SVR of 15 relapse patients 
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3.6.3.  Viral load changing during treatment and after treatment of relapse 
patients 
 
The baseline viral load of most relapse patients were less than 800,000.  These 
initial values were lower than most patients without relapse group. Only one patient 
(P207) relapse with SVR12 76800 declined to negative zero during SVR24. 
 
 
 
 
 
Fig. 40.  Viral load changing during treatment and after treatment  
of 15 relapse patients 
 
 
 
64 
 
 
3.6.4.  Genotype and treatment regimens of the relapse patients 
 
 
Patient Gender 
Treatment 
Duration Age Genotype 
Treatment 
regimens 
P030 Male 24 48 3a/b SOF DAC 
P070 Male 24 53 1b Harvoni 
P084 Female 24 56 3a/b SOF DAC 
P213 Male 24 49 3a/b Harvoni 
P214 Male 24 45 3a/b SOF 
P289 Male 24 52 3a/b SOF DAC 
P058 Male 12 54 1a SOF 
P091 Male 12 38 1b SOF DAC 
P094 Male 12 63 1b SOF 
P121 Male 12 45 3a/b SOF SMP 
P207 Female 12 43 1a SOF 
P375 Male 12 52 1b Harvoni 
P421 Female 12 55 1a SOF DAC 
P237 Male 8 45 1b Harvoni 
P407 Male 8 54 1a Harvoni 
Table 37.  Genotype and treatment regimens of the relapse patients 
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3.6.5.  Comorbidity and coinfection of relapse patients 
 
Among 15 relapsed patients, nine patients had liver cirrhosis, with significant 
statistical relevance. Only one relapse patient had liver transplantation, without 
statistical relevance. There is no relapse patient with nephrectomy during treatment. 
All the relapse patients without coinfection HIV. One relapse patient with HBV. 
 
Patient 
Liver 
cirrhosis 
Liver 
transplantation Nephrectomy 
Coinfection 
HIV 
Coinfection 
HBV 
P030 yes yes no no no 
P070 yes no no no no 
P084 yes no no no no 
P213 yes no no no no 
P214 yes no no no no 
P289 yes no no no no 
P058 yes no no no no 
P091 no no no no no 
P094 no no no no no 
P121 no no no no no 
P207 yes no no no no 
P375 yes no no no no 
P421 no no no no no 
P237 no no no no no 
P407 no no no no yes 
Table 38.  Comorbidity and Coinfection of relapse patients 
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3.6.6.  Pre-therapy of relapse patients 
   
 Among 15 relapse patients, there are half patients (7/15) with pre-therapy and half 
patients (8/15) without pre-therapy. 9 patients had taken medicine with IFN, 7 patients 
had taken medicine with RBV, and most relapse patients with pre-therapy had taken 
both medicines combined with IFN and RBV, and some patients had taken more 
several drugs such as PEG, IFN, RBV, TVR, NR. 
 
 
Patient Pre-therapy Pre-therapy with IFN RBV 
P030 yes RBV Without With 
P070 yes IFN, RBV With With 
P084 yes IFN, RBV With With 
P213 no Without Without 
P214 no Without Without 
P289 no Without Without 
P058 yes PEG, IFN, RBV With With 
P091 no Without Without 
P094 no Without Without 
P121 yes PEG, IFN, RBV  With With 
P207 no Without Without 
P375 yes RBV, IFN With With 
P421 yes PEG, IFN, RBV, TVR, NR With With 
P237 no Without Without 
P407 no Without Without 
Table 39.  Pre-therapy of relapse patients 
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3.6.7.  Baseline clinical chemistry of the relapse patients 
 
Patient Hemoglobin WBC Platelets INR Creatinine Bilirubin ALT 
P030 10 2690 69 1.2 1 
P070 8.9 1840 44 1.3 0.7 1.4 51 
P084 12 3260 75 0.6 1 49 
P213 13.9 3350 50 1.1 0.6 1 60 
P214 11.6 4710 132 1.3 0.5 2.3 105 
P289 12.7 5240 88 1.1 1 1.7 37 
P058 17.1 8090 76 0.8 57 
P091 18 5240 244 1 0.9 0.6 88 
P094 17.6 7760 177 1.2 0.8 0.6 121 
P121 14.5 6370 287 1 0.8 0.5 191 
P207 13.5 4690 119 1.2 0.7 2.3 21 
P375 15.1 3860 105 1.3 0.7 1.4 106 
P421 13.5 6670 278 0.6 56 
P237 8.7 5060 43 1 1 0.4 29 
P407 15.9 6320 236 1 0.7 0.6 68 
Table 40.  Baseline clinical chemistry of the relapse patients 
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3.6.8.  Analysis viral load changing with time in relapse patients 
 
Patient Nr. 030 
 
Fig. 41.  Viral load changing with time in Hepatitis C relapse patient (P030) 
 
Patient P030 
Gender Male 
Age 48 
Genotype  3a/b 
Treatment duration 24  
Treatment regimens SOF DAC 
Liver cirrhosis yes 
Liver transplantation yes 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy yes 
Pre-therapy with RBV 
Hemoglobin 10 
WBC 2690 
PLT 69 
INR 1.2 
Creatinine 1 
Bilirubin no data 
ALT no data 
Baseline viral load   4890000 
Table 41.  Characteristics of Hepatitis C relapse patient (P030) 
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Patient Nr. 070 
 
 
Fig. 42.  Viral load changing with time in Hepatitis C relapse patient (P070) 
 
 
Patient P070 
Gender Male 
Age 53 
Genotype  1b 
Treatment duration 24 
Treatment regimens Harvoni 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy yes 
Pre-therapy with IFN, RBV 
Hemoglobin 8.9 
WBC 1840 
PLT 44 
INR 1.3 
Creatinine 0.7 
Bilirubin 1.4 
ALT 51 
Baseline viral load   105000 
Table 42.  Characteristics of Hepatitis C relapse patient (P070) 
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Patient Nr. 084 
 
 
Fig. 43.  Viral load changing with time in Hepatitis C relapse patient (P084) 
 
 
Patient P084 
Gender Female 
Age 56 
Genotype  3a/b 
Treatment duration 24 
Treatment regimens SOF DAC 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy yes 
Pre-therapy with IFN,RBV 
Hemoglobin 12 
WBC 3260 
PLT 75 
INR no data 
Creatinine 0.6 
Bilirubin 1 
ALT 49 
Baseline viral load   1380000 
Table 43.  Characteristics of Hepatitis C relapse patient (P084) 
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Patient Nr. 213 
 
 
Fig. 44.  Viral load changing with time in Hepatitis C relapse patient (P213) 
 
Patient P213 
Gender Male 
Age 49 
Genotype  3a/b 
Treatment duration 24 
Treatment regimens Harvoni 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy no 
Hemoglobin 13.9 
WBC 3350 
PLT 50 
INR 1.1 
Creatinine 0.6 
Bilirubin 1 
ALT 60 
Baseline viral load   8430 
SVR 12 590000 
SVR 24 1280000 
SVR 48 170000 
Table 44.  Characteristics of Hepatitis C relapse patient (P213) 
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Patient Nr. 214 
 
 
Fig. 45.  Viral load changing with time in Hepatitis C relapse patient (P214) 
 
 
Patient P214 
Gender Male 
Age 45 
Genotype  3a/b 
Treatment duration 24 
Treatment regimens SOF 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy no 
Hemoglobin 11.6 
WBC 4710 
PLT 132 
INR 1.3 
Creatinine 0.5 
Bilirubin 2.3 
ALT 105 
Baseline viral load   1740000 
Table 45.  Characteristics of Hepatitis C relapse patient (P214) 
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Patient Nr. 289 
 
 
Fig. 46.  Viral load changing with time in Hepatitis C relapse patient (P289) 
 
 
Patient P289 
Gender Male 
Age 52 
Genotype  3a/b 
Treatment duration 24 
Treatment regimens SOF DAC 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy no 
Hemoglobin 12.7 
WBC 5240 
PLT 88 
INR 1.1 
Creatinine 1 
Bilirubin 1.7 
ALT 37 
Baseline viral load   3160000 
Table 46.  Characteristics of Hepatitis C relapse patient (P289) 
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Patient Nr. 058 
 
 
Fig. 47.  Viral load changing with time in Hepatitis C relapse patient (P058) 
 
 
Patient P058 
Gender Male 
Age 54 
Genotype  1a 
Treatment duration 12 
Treatment regimens SOF 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy yes 
Pre-therapy with PEG, IFN, RBV 
Hemoglobin 17.1 
WBC 8090 
PLT 76 
INR no data 
Creatinine no data 
Bilirubin 0.8 
ALT 57 
Baseline viral load   10300 
Table 47.  Characteristics of Hepatitis C relapse patient (P058) 
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Patient Nr. 091 
 
 
 
Fig. 48.  Viral load changing with time in Hepatitis C relapse patient (P091) 
 
 
Patient P091 
Gender Male 
Age 38 
Genotype  1b 
Treatment duration 12 
Treatment regimens SOF DAC 
Liver cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy no 
Hemoglobin 18 
WBC 5240 
PLT 244 
INR 1 
Creatinine 0.9 
Bilirubin 0.6 
ALT 88 
Baseline viral load   3390000 
Table 48.  Characteristics of Hepatitis C relapse patient (P091) 
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Patient Nr. 094 
 
 
Fig. 49.  Viral load changing with time in Hepatitis C relapse patient (P094) 
 
 
Patient P094 
Gender Male 
Age 63 
Genotype  1b 
Treatment duration 12 
Treatment regimens SOF 
Liver cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy no 
Hemoglobin 17.6 
WBC 7760 
PLT 177 
INR 1.2 
Creatinine 0.8 
Bilirubin 0.6 
ALT 121 
Baseline viral load   321000 
Table 49.  Characteristics of Hepatitis C relapse patient (P094) 
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Patient Nr. 121 
 
 
Fig. 50.  Viral load changing with time in Hepatitis C relapse patient (P121) 
 
 
Patient P121 
Gender Male 
Age 45 
Genotype  3a/b 
Treatment duration 12 
Treatment regimens SOF SMP 
Liver cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy yes 
Pre-therapy with PEG, IFN, RBV  
Hemoglobin 14.5 
WBC 6370 
PLT 287 
INR 1 
Creatinine 0.8 
Bilirubin 0.5 
ALT 191 
Baseline viral load   4910000 
Table 50.  Characteristics of Hepatitis C relapse patient (P094) 
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Patient Nr. 207 
 
 
Fig. 51.  Viral load changing with time in Hepatitis C relapse patient (P207) 
 
 
Patient P207 
Gender Female 
Age 43 
Genotype  1a 
Treatment duration 12 
Treatment regimens SOF 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy no 
Hemoglobin 13.5 
WBC 4690 
PLT 119 
INR 1.2 
Creatinine 0.7 
Bilirubin 2.3 
ALT 21 
Baseline viral load   408000 
Table 51.  Characteristics of Hepatitis C relapse patient (P207) 
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Patient Nr. 375 
 
 
Fig. 52.  Viral load changing with time in Hepatitis C relapse patient (P375) 
 
 
Patient P375 
Gender Male 
Age 52 
Genotype  1b 
Treatment duration 12 
Treatment regimens Harvoni 
Liver cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy yes 
Pre-therapy with RBV, IFN 
Hemoglobin 15.1 
WBC 3860 
PLT 105 
INR 1.3 
Creatinine 0.7 
Bilirubin 1.4 
ALT 106 
Baseline viral load   862000 
Table 52.  Characteristics of Hepatitis C relapse patient (P375) 
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Patient Nr. 421 
 
 
Fig. 53.  Viral load changing with time in Hepatitis C relapse patient (P421) 
 
Patient P421 
Gender Female 
Age 55 
Genotype  1a 
Treatment duration 12 
Treatment regimens SOF DAC 
Liver cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy yes 
Pre-therapy with PEG, IFN, RBV, TVR, NR 
IFN Without 
RBV Without 
Hemoglobin 13.5 
WBC 6670 
PLT 278 
INR no data 
Creatinine no data 
Bilirubin 0.6 
ALT 56 
Baseline viral load   3030000 
Table 53.  Characteristics of Hepatitis C relapse patient (P421) 
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Patient Nr. 237 
 
 
Fig. 54.  Viral load changing with time in Hepatitis C relapse patient (P237) 
 
 
Patient P237 
Gender Male 
Age 45 
Genotype  1b 
Treatment duration 8 
Treatment regimens Harvoni 
Liver cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV no 
Pre-therapy no 
Hemoglobin 8.7 
WBC 5060 
PLT 43 
INR 1 
Creatinine 1 
Bilirubin 0.4 
ALT 29 
Baseline viral load   469000 
Table 54.  Characteristics of Hepatitis C relapse patient (P237) 
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Patient Nr. 407 
 
 
Fig. 55.  Viral load changing with time in Hepatitis C relapse patient (P407) 
 
Patient P407 
Gender Male 
Age 54 
Genotype  1a 
Treatment duration 8 
Treatment regimens Harvoni 
Liver cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV yes 
Pre-therapy no 
Hemoglobin 15.9 
WBC 6320 
PLT 236 
INR 1 
Creatinine 0.7 
Bilirubin 0.6 
ALT 68 
Baseline viral load   2180000 
Table 55.  Characteristics of Hepatitis C relapse patient (P407) 
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3.6.8.  Analysis correlation of relapse by Multiple factors 
 
All factors that may affect the relapse were analyzed by statistical correlation 
method, including gender, age, genotype, initial viral load, treatment regimens, 
coinfection HIV, coinfection HBV, liver cirrhosis, liver transplantation, nephrectomy, 
pre-therapy, etc. Treatment duration, liver cirrhosis, baseline PLT has a significant 
statistical correlation to the relapse. 
 
3.6.9.  Analysis correlation of relapse by treatment duration 
 
Correlation analysis for relapse and treatment duration, there was a statistically 
significant correlation between the relapse and the treatment duration, P=0.0174* 
(P<0.05). Relapse patients with 24 weeks treatment duration had the highest 
proportion. 
 
 
Fig. 56.  Logistic curve fitting of relapse by treatment duration (P<0.001**) 
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Fig. 57.  Logistic fitting of relapse by treatment duration 
 
 
 
Count 
Row % 
Without 
relapse Relapse Total 
12 weeks 294 97.67 
7 
2.33 301 
24 weeks 68 91.89 
6 
8.11 74 
8 weeks 43 95.56 
2 
4.44 45 
Total 405 15 420 
 
Table 56.  Contingency of treatment duration by Relapse 
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3.6.10.  Analysis correlation of relapse by Liver cirrhosis 
Correlation analysis for relapse and liver cirrhosis P=0.0056*（P<0.05）There 
was a statistically significant correlation between the relapse and the cirrhosis. 
 
 
Fig. 58.  Correlation between relapse and Liver cirrhosis  (P=0.0056*) 
 
 
 
 
Count 
Row % 
Without 
relapse Relapse Total 
Non-cirrhotic 
patients 
295 
98.01 
6 
1.99 301 
 
Liver cirrhosis 
110 
92.44 
9 
7.32 119 
Total 405 15 420 
Table 57.  Contingency of liver cirrhosis by relapse (P=0.0056*) 
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3.6.11.  Analysis relapse correlation by Liver cirrhosis 
 
 
Fig. 59.  Logistic fitting of relapse by baseline viral load  (P<0.001*) 
 
 
 
3.6.12.  Analysis correlation of relapse by baseline viral load 
 
 
Fig. 60.  Baseline viral load of relapse patients 
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3.6.13.  Analysis correlation of relapse by age 
 
 
Fig. 61.  Relapse correlation with age 
 
 
 
Count 
Row % 
Relapse SVR12  
negative 
Total 
Age<60 14 
4.26 
315 
95.74 
329 
Age>60 1 
0.93 
107 
99.07 
108 
Total 15 422 437 
Table 58.  Analysis relapse by age 
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3.6.14.  Analysis correlation of relapse by genotype 
 
 
 
Fig. 62.  Relapse correlation with genotype 
 
 
 
3.6.15.  Analysis correlation of relapse by gender 
 
 
Fig. 63.  Relapse correlation with gender 
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3.6.16.  Analysisc correlation of relapse by Liver cirrhosis 
 
 
Fig. 64.  Relapse correlation with Liver cirrhosis 
 
 
 
3.6.17.  Analysisc correlation of relapse by Liver transplantation 
 
 
Fig. 65.  Relapse correlation with Liver transplantation 
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3.7.  Hepatitis C patients coinfection with HIV or HBV 
 
3.7.1.  General characters of hepatitis C patients coinfection with HIV or HBV 
There are 8 coinfection patients in hepatitis C patients: 6 patients coinfection 
with HIV, 2 patients coinfection with HBV.  Only one patient is female (P029, 
coinfection HIV), the gender ratio shows male patients (7/8, 87.5%) obviously more 
than female patients (1/8, 12.5%), with significant statistical differences (P<0.01).  
The treatment duration included 24 weeks, 12 weeks and 8 weeks. There are four 
coinfection patients had 24 weeks treatment duration (4/8, 50%), three patients had 12 
weeks treatment duration (3/8, 37.5%), and only one patient had 8 weeks duration 
(1/8, 12.5%).  
The age of all coinfection HIV or HBV patients range from 43 (Min) to 72 (Max), 
the average age was 54.75±8.69 (MV±SD).  
All the patients coinfection with HIV or HBV included only three kinds of 
genotypes: 1a (5/8, 62.5%); 3a/b (1/8, 12.5%); 4 (2/8, 25%). All the patient's 
coinfection with HBV had only one genotypes 1a. 
The treatment regiments includes SOF (1/8, 12.5%); SOF DAC (3/8, 50%); 
Harvoni (2/8,37.5%). 
Among eight coinfection patients, there are six patients without pre-therapy and 
two patients with pre-therapy with IFN and RBV 
 
3.7.2.  Special patients and relapse hepatitis C patients coinfection with HIV or 
HBV 
Among eight coinfection patients, The number of special patients combined with 
liver cirrhosis is 3 (37.5%) all from HIV; is two patients with liver transplantation (1 
HIV, 1 HBV). There are no patients combined with nephrectomy in the coinfection 
HIV or HBV patients. 
After treatment, there are only one relapse patients (P407, HBV) SVR12 with 
high viral load (1.270.000 IU/mL >800.000 IU/mL); 
91 
 
 
Coinfection with HIV or HBV patients  n        %          N=8 
Coinfection 
HIV 
HBV 
 
6   (6/437,  1.37%) 
2   (2/437,  0.46%) 
Gender  
Male 
Female 
 
7   (7/8,  87.5%)  P<0.01%* 
1   (1/8,  12.5%) 
Age   
Mean±SD  (Min - Max) 
>60 yr 
 
54.75±8.69   (43 - 72) 
1   (1/8,  12.5%) 
Genotype 
1a 
3a/b 
4 
 
5  （62.5%） (3 HIV, 2 HBV) 
2  （25%）   (2 HIV) 
1  （12.5%）  (1 HIV) 
Relapse 
HIV 
HBV 
 
0 
1 
Treatment duration 
24 weeks 
12 weeks 
8 weeks 
 
4   (40%), 
3   (37.5%) 
1   (12.5%) 
Treatment regimens 
SOF 
SOF DAC 
Harvoni 
 
1  (12.5%) 
4   (40%), 
3   (37.5%) 
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Special patients 
Liver cirrhosis 
Liver transplantation 
Nephrectomy 
 
3  (37.5%)  (3 HIV) 
2 （25%）  (1 HIV, 1 HBV)  
0 
Pre-therapy 
With 
without 
 
2  (25%) 
6  (75%) 
Baseline platelet count 
Low platelets  (≤100/nL) 
 
2  (25%) 
Baseline viral load 
<800.000 IU/mL   Low viral load 
≥800.000 IU/mL   High viral load 
≥6.000.000 IU/mL  Very high viral load 
≥25.000.000 IU/mL Very high viral load 
 
3  (37.5%) 
5  (62.5%) 
2  (25%) 
0 
SVR 12 rate 
HIV 
HBV 
 
6/6  (100%) 
1/2  (50%)   
Baseline clinical chemistry 
ALT        (IU/1) 
Platelets     (thousand/μL) 
WBC       ( /uL) 
Hemoglobin  (g/dL) 
Creatinine    (mg/dL) 
Total Bilirubin (mg/dL) 
INR       
Mean ± SD    (Min - Max) 
1856.63±30.78  (18-99) 
173.75±103.52  (42-344) 
7010.00±2024.97  (4710-11170) 
13.53±1.89  (11.2-16.6) 
0.76±0.21  (0.6-1.1) 
11.53±27.81  (0.3-80.2) 
1.06±0.15 (0.9-1.3) 
Table 59.  Characteristics of hepatitis C patients coinfection with HIV or HBV 
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3.7.3.  Proportion of hepatitis C patients coinfection with HIV or HBV 
 
Fig. 66.  Proportion of hepatitis C patients coinfection with HIV or HBV 
 
3.7.4.  Characteristics of hepatitis C patients coinfection with HIV 
 
Patient PCR 0 PCR 2 PCR4 PCR 8 PCR12 PCR18 PCR24 SVR 4 SVR12 SVR 24 SVR48 
P012 1260000 0 0 0 0 
P029 4830000 0 <15 0 0 0 0 0 
P041 3210 0 0 0 
P097 254000 <15 0 0 0 0 0 0 0 0 
P242 684000 49 0 0 0 0 
P328 6970000 0 0 
Table 60.  Viral load of hepatitis C patients coinfection with HIV 
 
Patient Gender Age Genotype 
Treatment 
regiment 
Treatment 
duration 
Treatment 
completed 
Pre- 
therapy 
P012 Male 72 3a/b SOF 24 completed no 
P029 Female 56 1a SOF DAC 24 completed no 
P041 Male 53 1a Harvoni 12 completed no 
P097 Male 43 4 SOF DAC 24 completed no 
P242 Male 58 1a SOF DAC 12 completed no 
P328 Male 56 4 Harvoni 12 completed yes 
Table 61.  General characteristics of hepatitis C patients coinfection with HIV  
0.5% 1.37%
98%
Coinfection HBV
Coinfection HIV
Without coinfection
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Patient Relapse HIV HBV 
Liver 
Cirrhosis 
Liver 
transplantation Nephrectomy 
P012 no yes no no no no 
P029 no yes no yes no no 
P041 no yes no yes no no 
P097 no yes no yes yes no 
P242 no yes no no no no 
P328 no yes no no no no 
Table 62.  Complication of coinfection HIV patients 
 
Patient Hemoglobin WBC PLT Quick INR Creatinine Bilirubin ALT 
P012 13.9 6830 123 1.1 1.3 39 
P029 13.4 5730 116 78 1.1 1.3 34 
P041 12 4710 156 57 1.3 0.8 2.1 33 
P097 13 6180 42 6 99 
P242 16.6 11170 282 >120 0.9 0.6 0.4 63 
P328 12.2 8720 344 106 1 0.6 0.3 18 
Table 63.  Baseline clinical chemistry of coinfection HIV patients 
 
 
 
Fig. 67.  Viral load changing with time of HCV coinfection HIV 
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3.7.5.  Characteristics of hepatitis C patients coinfection with HBV 
 
 
Patient PCR 0 PCR 2 PCR4 PCR 8 PCR12 PCR18 PCR24 SVR 4 SVR12 SVR 24 SVR48 
P024 13200000 0 0 0 0 0 
P407 2180000 0 1270000 
Table 64.  Viral load of hepatitis C patients coinfection with HBV 
 
 
Patient Gender Age Genotype 
Treatment 
regiment 
Treatment 
duration 
Treatment 
completed 
Pre- 
therapy 
P024 Male 46 1a SOF DAC 24 completed yes 
P407 Male 54 1a Harvoni 8 relapse no 
Table 65.  General characteristics of hepatitis C patients coinfection with HBV 
 
 
 
Patient Relapse HIV HBV 
Liver 
Cirrhosis 
Liver 
transplantation Nephrectomy 
P024 no no yes no yes no 
P407 yes no yes no no no 
Table 66.  Complication of hepatitis C patients coinfection with HBV 
 
 
 
Patient Hemoglobin WBC PLT Quick INR Creatinine Bilirubin ALT 
P024 11.2 6420 91 80.2 99 
P407 15.9 6320 236 96 1 0.7 0.6 68 
Table 67.  Baseline clinical chemistry of hepatitis C patients coinfection with 
HBV 
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3.7.6.  Viral load changing with time in hepatitis C patients coinfection HIV  
 
Patient Nr. 012 
 
Fig. 68.  Viral load changing with time in hepatitis C patients coinfection with HIV 
(P012) 
 
Patient P012 
Gender Male 
Age 72 
Genotype 3a/b 
Treatment regiment SOF 
Treatment duration (Weeks) 24 
Treatment completed completed 
Relapse no 
HIV yes 
HBV no 
Liver Cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Pre-therapy no 
Hemoglobin 13.9 
WBC 6830 
PLT 123 
INR 
Creatinine 1.1 
Bilirubin 1.3 
ALT 39 
Baseline viral load 1260000 
Table 68.  Characteristics of in hepatitis C patients coinfection with HIV (P012) 
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Patient Nr. 029 
 
 
Fig. 69.  Viral load changing with time in hepatitis C patients coinfection with HIV 
(P029) 
 
Patient P029 
Gender Female 
Age 56 
Genotype 1a 
Treatment regiment SOF DAC 
Treatment duration (Weeks) 24 
Treatment completed completed 
Relapse no 
HIV yes 
HBV no 
Liver Cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Pre-therapy no 
Hemoglobin 13.4 
WBC 5730 
PLT 116 
INR 1.1 
Creatinine 
Bilirubin 1.3 
ALT 34 
Baseline viral load 4830000 
Table 69.  Characteristics of in hepatitis C patients coinfection with HIV (P029) 
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Patient Nr. 041 
 
Fig. 70.  Viral load changing with time in hepatitis C patients coinfection with HIV 
(P041) 
Patient P041 
Gender Male 
Age 53 
Genotype 1a 
Treatment regiment Harvoni 
Treatment duration (Weeks) 12 
Treatment completed completed 
Relapse no 
HIV yes 
HBV no 
Liver Cirrhosis yes 
Liver transplantation no 
Nephrectomy no 
Pre-therapy no 
Hemoglobin 12 
WBC 4710 
PLT 156 
INR 1.3 
Creatinine 0.8 
Bilirubin 2.1 
ALT 33 
Baseline viral load 3210 
Table 70.  Characteristics of in hepatitis C patients coinfection with HIV (P041) 
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Patient Nr. 097 
 
 
Fig. 71.  Viral load changing with time in hepatitis C patients coinfection with HIV 
(P097) 
 
Patient P097 
Gender Male 
Age 43 
Genotype 4 
Treatment regiment SOF DAC 
Treatment duration (Weeks) 24 
Treatment completed completed 
Relapse no 
HIV yes 
HBV no 
Liver Cirrhosis yes 
Liver transplantation yes 
Nephrectomy no 
Pre-therapy no 
Hemoglobin 13 
WBC 6180 
PLT 42 
INR 
Creatinine 
Bilirubin 6 
ALT 99 
Baseline viral load 254000 
Table 71.  Characteristics of in hepatitis C patients coinfection with HIV (P097) 
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Patient Nr. 242 
 
 
Fig. 72.  Viral load changing with time in hepatitis C patients coinfection with HIV 
(P242) 
 
Patient P242 
Gender Male 
Age 58 
Genotype 1a 
Treatment regiment SOF DAC 
Treatment duration (Weeks) 12 
Treatment completed completed 
Relapse no 
HIV yes 
HBV no 
Liver Cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Pre-therapy no 
Hemoglobin 16.6 
WBC 11170 
PLT 282 
INR 0.9 
Creatinine 0.6 
Bilirubin 0.4 
ALT 63 
Baseline viral load 684000 
Table 72.  Characteristics of in hepatitis C patients coinfection with HIV (P242) 
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Patient Nr. 328 
 
 
Fig. 73.  Viral load changing with time in hepatitis C patients coinfection with HIV 
(P328) 
 
Patient P328 
Gender Male 
Age 56 
Genotype 4 
Treatment regiment Harvoni 
Treatment duration (Weeks) 12 
Treatment completed completed 
Relapse no 
HIV yes 
HBV no 
Liver Cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Pre-therapy yes 
Hemoglobin 12.2 
WBC 8720 
PLT 344 
INR 1 
Creatinine 0.6 
Bilirubin 0.3 
ALT 18 
Baseline viral load 6970000 
Table 73.  Characteristics of in hepatitis C patients coinfection with HIV (P328) 
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3.7.7  Viral load changing with time in Hepatitis C patients coinfection HBV  
 
Patient Nr. 024 
 
Fig. 74.  Viral load changing with time in hepatitis C patients coinfection with HIV 
(P024) 
Patient P024 
Gender Male 
Age 46 
Genotype 1a 
Treatment regiment SOF DAC 
Treatment duration (Weeks) 24 
Treatment completed completed 
Relapse no 
HIV no 
HBV yes 
Liver Cirrhosis no 
Liver transplantation yes 
Nephrectomy no 
Pre-therapy yes 
Hemoglobin 11.2 
WBC 6420 
PLT 91 
INR no data 
Creatinine no data 
Bilirubin 80.2 
ALT 99 
Baseline viral load 13200000 
Table 74.  Characteristics of in hepatitis C patients coinfection with HBV (P024) 
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Patient Nr. 407 
 
 
Fig. 75.  Viral load changing with time in hepatitis C patients coinfection with HBV 
(P407) 
 
Patient P407 
Gender Male 
Age 54 
Genotype  1a 
Treatment duration 8 
Treatment regiments Harvoni 
Liver cirrhosis no 
Liver transplantation no 
Nephrectomy no 
Coinfection HIV no 
Coinfection HBV yes 
Pre-therapy no 
Hemoglobin 15.9 
WBC 6320 
PLT 236 
INR 1 
Creatinine 0.7 
Bilirubin 0.6 
ALT 68 
Baseline viral load   2180000 
Table 75.  Characteristics of in hepatitis C patients coinfection with HBV (P407) 
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3.8  HCV patients with liver cirrhosis  
 
3.8.1  Special patients population 
 
Comorbidity N     % 
Liver cirrhosis 123  (28.15%) 
Liver transplantation 22   (5.03%) 
Nephrectomy 6    (1.37%) 
Table 76.  Special patients population 
 
 
 
 
Fig. 76.  The proportion of patients with comorbidity 
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3.8.2  The proportion of hepatitis C patients with liver cirrhosis 
 
 
Fig. 77.  The proportion of hepatitis C patients with liver cirrhosis 
 
 
3.8.3  Treatment regimens of liver cirrhosis patients 
 
Treatment regimens Number of patients Proportion 
Epclusa 
Exviera+Viekirax 
Harvoni 
SOF 
SOF DAC 
SOF SMP 
Zepatier 
6 
7 
36 
12 
45 
16 
1 
4.88% 
5.69% 
29.27% 
9.76% 
36.59% 
13.01% 
0.81% 
Total 123 100% 
Table 77.  Treatment regimens of liver cirrhosis patients 
 
 
123
28%
314
72%  
With liver cirrhosis
Without Liver cirrhosisis
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3.8.4  Characteristics of hepatitis C patients with liver cirrhosis 
 
Liver cirrhosis patients  n,  %          N=123 
Gender  
Male 
Female 
 
81  (65.85%) 
42  (34.15%) 
Age   
Mean±SD  (Min-Max) 
≥60 yr 
≥80 yr 
 
55.82±10.97  (28 - 84) 
28  (22.76%) 
3   (1.62%) 
Treatment duration 
12 weeks 
24 weeks 
Termination (Death) 
 
69  (56.56%) 
53  (43.44%), 
1   (6.67%).  
Genotype 
1a 
1b 
1 unclassified 
2a/b 
3a/b 
4 
5 
6 
 
32   (26.01%) 
48   (39.02%) 
1    (0.81%) 
4    (3.25%) 
26   (21.14%) 
10   (8.13%) 
1    (0.81%) 
1    (0.81%) 
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Treatment regimens 
Epclusa 
Exviera+Viekirax 
Harvoni 
SOF 
SOF DAC 
SOF SMP 
Zepatier 
 
6   （4.88%） 
7   （5.69%） 
36   （29.27%） 
12   （9.76%） 
45   （36.59%） 
16   （13.01%） 
1    （0.81%） 
Special patients 
Liver transplantation 
Nephrectomy 
Death 
 
7   (5.69%) 
2   (1.64%) 
1   (0.81%) 
Coinfection 
HBV 
HIV 
 
0  
3  (2.44%) 
Pre-thrapy 
With 
without 
 
76  (61.79%) 
47  (38.21%) 
Baseline platelet count 
Low platelets  (≤100/nL) 
 
57  (46.34%) 
Baseline viral load 
<800.000 IU/mL   Low viral load 
≥800.000 IU/mL   High viral load 
≥6.000.000 IU/mL  Very high viral load 
 
51  (41.46%) 
72  (58.53%) 
4   (3.25%)  
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Relapse 
With 
Without 
 
9    (7.32%) 
114  (92.69) 
SVR 12  
Negative 
Positive 
 
9    (7.32%) 
114  (92.69) 
Baseline clinical chemistry 
 
Hemoglobin      (g/dL) 
WBC           ( /μL) 
PLT            (1000/μL) 
Quick 
INR            (INR) 
Creatinine       (mg/dL) 
Bilirubin        (mg/dL) 
ALT           (IU/1)  
Mean±SD  (Min - Max) 
 
13.45±1.99      (8.4-17.5) 
5265.92±2165.00（1520-12710） 
113.28± 62.74  （23-366） 
75.88±20.07    （28-121） 
1.24±0.42      （0.9-4.4） 
0.74±0.25      （0-2.2） 
1.58±2.39      （0.3-23.6） 
81.90±55.04    （20-295） 
 
Table 78.  Characteristics of liver cirrhosis patients 
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3.8.5  Age analysis of liver cirrhosis patients 
   
 
Fig. 78.  Age distribution of liver cirrhosis patients 
 
 
Fig. 79.  Logistic fitting of age by SVR12 outcome in liver cirrhosis patients 
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3.8.6  Gender analysis of hepatitis C patients with/without liver cirrhosis 
 
Fig. 80.  Liver cirrhosis proportion by gender in hepatitis C patients 
 
 
3.8.7  Time duration of hepatitis C patients with/without liver cirrhosis 
 
 
Fig. 81.  Time duration of hepatitis C patients with/without liver cirrhosis  
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3.8.8  Genotype analysis of liver cirrhosis patients 
 
Fig. 82.  Genotype proportion of liver cirrhosis patients 
 
3.8.9  Baseline viral load analysis of liver cirrhosis patients 
 
 
Fig. 83.  Distribution of age in liver cirrhosis patients 
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3.8.10  Analysis liver cirrhosis patients by baseline viral load 
 
Fig. 84.  Logistic fitting of SVR12 rate by baseline viral load 
in liver cirrhosis patients （P<0.001*） 
 
3.8.11  Treatment regimens of liver cirrhosis patients 
 
 
Fig. 85.  Treatment regimens of liver cirrhosis patients 
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3.8.12  Analysis SVR12 outcome of different genotype in liver cirrhosis patients  
(117 liver cirrhosis patients, exclude 5 patients of death, termination and lost 
to follow-up) 
 
Fig. 86.  Proportion of SVR12 negative vs. relapse by different genotype  
in liver cirrhosis patients  
Count 
Row % 
SVR 12 
negative 
Relapse Total 
1 
unclassified 
1 
100.00 
0 
0.00 
1 
1a 29 
93.55 
2 
6.45 
31 
1b 42 
95.45 
2 
4.55 
44 
2a/b 4 
100.00 
0 
0.00 
4 
3a/b 21 
80.77 
5 
19.23 * 
26 
4 9 
100.00 
0 
0.00 
9 
5 1 
100.00 
0 
0.00 
1 
6 1 
100.00 
0 
0.00 
1 
Total 108 9 117 
 
Table 79.  Proportion of SVR12 negative vs. relapse in different genotype of liver cirrhosis patients 
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6
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3.8.13  Analysis SVR12 negative vs. relapse of different treatment regimens  
(117 liver cirrhosis patients, exclude 5 patients of death, termination and lost to 
follow-up) 
 
Fig. 87.  SVR12 outcome of treatment regimens in liver cirrhosis patients 
 
Count 
Row % Negative Relapse Total 
Epclusa 6 100.00 
0 
0.00 6 
Exviera+Viekirax 6 100.00 
0 
0.00 6 
Harvoni 31 91.18 
3 
8.82 34 
SOF 9 75.00 
3 
25.00 12 
SOF DAC 42 93.33 
3 
6.67 45 
SOF SMP 14 100.00 
0 
0.00 14 
Zepatier 0 0 0 
Total 108 9 117 
Table 80.  Proportion of SVR12 negative vs. relapse of treatment regimens  
(117 liver cirrhosis patients, exclude 5 patients of death, termination and lost to follow-up) 
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4.  Discussion 
 
Hepatitis C virus infections are world wild existing, and HCV is a major cause of 
liver cirrhosis and liver cancer. Therefore, to treat chronic HCV infection has a major 
impact on morbidity and mortality of liver diseases in human being. About two 
decades before, the standard treatment was based on ribavirin and interferon. But the 
success rate of treatment was less than 50%. From recent years, the direct-acting 
antivirals (DAAs) became available with much higher treatment success rate of more 
than 90%, and the treatment duration is much shorter.    
 
4.1.  Overall SVR12 rate 
In this retrospective study of hepatitis C treatment with direct-acting antivirals, 
the overall outcome in the cohort shows SVR12 rate of total 437 patients is 95.95%. 
These data are similar to other study publications related DAA clinical research which 
the DAAs SVR12 rate achieved more than 90% (Asselah et al., 2016). The SVR12 
rate statistical correlation with liver cirrhosis (P=0.0016*, liver transplantation 
(P=0.0166), coinfection with HBV (P=0.0004), baseline platelets (P=0.0068). 
 
4. 2.  Genotypes 
In this study, the proportion of GT1 patients is the largest (310/437, 70.94%), 
which includes GT1a (30.66%) and GT1b (39.59%), followed by the GT3 (20.37%).  
Among the six genotypes, GT1a achieved the highest SVR12 rate (96.92%), followed 
by GT1b (95.78%). GT3 had the lowest SVR12 rate (93.02%). The relapse rate of 
GT3 (6.98%) is double times compared with of GT1 relapse rate (3.08% of GT1a, 
3.01% of GT1b). 
As recently published, the SVR12 rate of DAAs for GT3 is significantly less than 
for GT1, GT1a, GT1b. In this study, the SVR12 rate for GT3 was 90%, for GT1a 95%, 
for GT1b 93% (Werner et al., 2016). 
It is necessary to further develop new direct antiviral combinations to improve the 
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success rate of GT3 HCV treatment. 
Although the SVR12 rates of GT4, GT5, GT6, GT1 unclassified were up to 100%,  
the patient's numbers with these genotypes were small: GT4 (23/437), GT5 (2/437), 
GT6 (3/437), GT1 unclassified (3/437) respectively. So these genotype groups may 
not show the actual success rate of treatment.  
Genotypes have a distinct geographical difference globally (Gower et al., 2014). 
The genotypes of European countries mainly consist with GT1, followed by GT3. The 
population of GT4, GT5, GT6 are rare (Gower et al., 2014). 
There are five DAAs treatment options for GT1 suggested by EASL ( European 
Association for the study of the liver): 1 SOF/LDV (sofosbuvir and ledipasvir); 2  
SOF/VEL (sofosbuvir and velpatasvir); 3 GZR/EBR (grazoprevir and elbasvir); 4 
SOF/DAC (sofosbuvir and daclatasvir); 5 ritonavir-boosted paritaprevir, ombitasvir 
and dasabuvir (EASL, 2017).  
   In this study, GT1a patients were treated with six treatment regimens, GT1b with 
seven treatment regimens. The main treatment regimens for GT1 is SOF/LDV 
(Harvoni) (157/310, 48.39%), followed by SOF/DAC (60/310, 19.35%) and 
Exviera/Viekirax (43/310, 13.87%). The SVR12 rate of SOF/LDV is: for GT1a 
98.73%, for GT1b 95.31%. This result is similar to previous studies, three studies 
related GT1 using the SOF/LDV treatment regimen, the SVR12 rates were more than 
95% (Afdhal et al., 2014a, Afdhal et al., 2014b, Kowdley et al., 2014).  
There are two DAAs treatment options for GT3 suggested by EASL: 1 SOF/VEL 
(sofosbuvir and velpatasvir), 2 SOF/DAC (sofosbuvir and daclatasvir). In this study, 
six treatment regimens were used in GT3 patients. The main treatment regimen for 
GT3 is SOF/DAC (44/89, 49.44%), followed by SOF (27/89, 30.34%) and SOF/VEL 
(Eplusa) (13/89, 14.60%). The SVR12 rates for these three main treatment regimens 
of GT3 are SOF/DAC (93.18%), SOF (96.15%), SOF/VEL (Eplusa)(100%). A phase 
Ⅲ study with SOF/DAC in GT3 shows: the SVR12 rate for noncirrhotic patients was 
94% to 97%, for liver cirrhosis patients, it was 58% to 69% (Nelson et al., 2015). 
Another study showed 86% SVR12 rate in GT3 patients taking SOF/DAC (Leroy et 
al., 2016). 
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4.3.  Treatment regimens 
Seven treatment regimens were used for the six different genotypes. By 
comparing the SVR12 rate of the seven different direct-acting antivirals, SOF/LDV 
(Harvoni) achieved the highest SVR12 rate (96.71%), and also the largest proportion 
of all 437 hepatitis C patients (160/437, 36.61%) had taken it. The SVR12 rate for 
SOF/LDV in non-cirrhotic patients was 98.31% (116/118), for SOF/LDV with liver 
cirrhosis patients, it was 91.18% (31/34). This SVR12 rate is similar to the result of a 
previous study (Asselah et al., 2016). SOF/LDV SVR12 average rate of three studies 
is 97% (Asselah et al., 2016). In three studies of non-cirrhotic patients with SOF/LDV, 
the SVR12 rates were 99%, 95%, 94% respectively (Afdhal et al., 2014a, Afdhal et al., 
2014b, Kowdley et al., 2014). The SVR12 rates of liver cirrhosis patients with 
SOF/LDV were 94%, 86%, showed in two studies (Afdhal et al., 2014a, Afdhal et al., 
2014b). 
In this study, the SVR12 rate for SOF/DAC was 95.28%, and for SOF it was 
93.94%. The lowest SVR12 rate was seen for SOF/SMP (91.18%). The SVR12 rate 
for exviera/viekirax, epclusa (SOF/VEL), zepatier (GZR/EBR) achieved 100%. 
However, the number of patients taking SOF/SMP (34/437), exviera/viekirax (49/437), 
epclusa (SOF/VEL) (16/437), zepatier (GZR/EBR) (4/437) were small, so these 
DAAs groups may not be representative. In some studies, the SVR12 rates of 
GZR/EBR were 94% and 95% (Roth et al., 2015, Zeuzem et al., 2015). The SVR12 
rate of SOF/VEL was up to 99% (Foster et al., 2015, Feld et al., 2015). 
 
4.4.  Viral load 
In all 437 patients, the viral load declined to negative during treatment. The 
declining speed of viral load was very high. The majority of patients viral load had 
dropped to 0 or <15 in the fourth week. In some patients, the viral load rapidly 
declined to negative at the second week. 
The speed of viral load decreasing in the first two weeks cannot be calculated 
accurately because parts of the data in the first two weeks were not available. So it is 
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possible, that more patients turned to negative already within two weeks, or even 
earlier.  
The treatment duration of the previous standard treatments with ribavirin and 
interferon was 24 to 48 weeks, and the cure rate was about 50%. In comparison to the 
previous treatment, the DAAs treatment time is significantly reduced. The side effects 
of DAAs are also much milder than in previous treatment. 
Interestingly, our results show that patients with high viral load (>800,000 
IU/mL) have a higher SVR12 rate compared to patients with low viral load (<800,000 
IU/mL). All the patients with high viral load (>6,000,000 IU/mL) and very high viral 
load (>25,000,000 IU/mL) achieved 100% SVR12 rates. The patients with very high 
viral load declined with faster speed and without relapse. This result is inconsistent 
with previous clinical studies. These studies of the old treatment with ribavirin and 
interferon have shown that patients with high baseline viral load levels are more 
difficult to treat and had lower SVR12 rates than the patients with low viral load 
(McHutchison et al., 1998). 
 
4.5  Gender 
Hepatitis C patients have a significant difference with gender. Analysing the 
proportion of all 437 hepatitis C infected patients, male patients (265/437, 60.6%) 
were obviously more than female patients (172/437, 39.4%). The SVR12 rate of male 
(94.53%) was lower than female (98.71%). The relapse proportion of male (12/15, 
80%) was four times more compared to female relapse rate (3/15, 20%), with 
statistically significant differences (P<0.05). The liver cirrhosis patients consisted of 
65.85% male (81/123) and 34.15% female (42/123). The liver transplantation patients 
consisted of 68.18% male (15/22) and 31.82% female (7/22). The two death during 
treatment were males. 
The HCV infection rate shows lower in women was confirmed by previous 
studies (Kenny-Walsh, 1999, Wiese et al., 2000). A study about anti-D immune 
globulin contaminated with HCV in Germany, about nine hundred women had 
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received this kind of hepatitis C virus contaminants, The result of twenty years 
followed up showed HCV chronic infection rate of these women was only 55% 
(Wiese et al., 2000). Another similar study in Ireland, about seven hundred pregnant 
women who received anti-D immune globulin contaminated with HCV, after 
seventeen years followed up, also found 55% HCV RNA positive rate (Kenny-Walsh, 
1999).  
 
4.6.  Relapse 
There are 15 patients relapsed in a total of 437 patients; the relapse rate is 3.57%. 
Multiple factors were analyzed for the relapse correlation, such as genotypes, 
treatment regimens, treatment duration, baseline viral load, age, gender, liver cirrhosis, 
liver transplantation, coinfection with HBV or HIV, baseline platelet, pre-therapy. 
Among these factors, the liver cirrhosis, baseline PLT, and the treatment duration 
correlated with the relapse.  
The relapse rate in liver cirrhosis patients (7.32%) was significantly higher than 
the noncirrhotic patients (1.99%) (P<0.01). This result is consistent with other 
previous publications (Afdhal et al., 2014a, Afdhal et al., 2014b, Kowdley et al., 
2014).  
Interestingly, the results showed that the longer the treatment time, the higher the 
relapse rate. The relapse rate of patients with 24 weeks treatment duration (8.11%) 
was significantly higher than patients with 8 weeks (4.44%) and 12 weeks (2.33%). 
Some studies have shown that the shorter treatment duration with the more possibility 
of relapse. The sustained virological response is likely more stable with the longer 
treatment time. The result of this study is inconsistent with previous studies. However, 
some factors are leading to longer treatment time (24 weeks), such as difficult to treat 
patients with liver cirrhosis or liver transplantation. 24 weeks treatment duration 
group included 70.76% liver cirrhosis patients and 29.33% non-cirrhotic patients.  
About half (53/123, 43.09%) of cirrhosis patients and liver transplant patients (15/22, 
68.18%) had 24 weeks treatment duration. The reason for higher relapse rate in the 24 
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weeks group is because of the patient's condition or comorbidity (liver cirrhosis), and 
not because of longer treatment time.   
Relapse patients mainly distributed in the 45-60 yr age range. Usually, the older 
patients (>60 yr) be considered difficult to treat. But in this study, the results showed 
that younger patients had the higher relapse rate (4.43%) compared to the older age 
group (0.96%). Only one relapse patient could be seen in the >60 yr age group, and no 
relapse patient was older than 65 yr. Some studies showed elderly patients with 
similar SVR12 rate to young patients, probably because of the second generation 
direct-acting antivirals have good tolerance and low toxicity characteristics 
(Sulkowski et al., 2016). 
Contrary to the previous studies，most of relapse patients were in the low 
baseline viral load range. The relapse rate of patients with low viral load (<800,000 
IU/mL) was higher than the patients with high viral load (>800,000 IU/mL), and no 
relapse patient was in the range of very high viral load (>6,000,000 IU/mL). Most of 
the relapse patient’s viral load after treatment stop is much higher than the baseline 
viral load. The changing trend of viral load after treatment showed diversity for each 
relapse individual. Some viral load was continuously rising during 24 or 48 weeks 
after treatment, while others were rising first and then declined after relapse. Only one 
patient was positive at SVR12 but has dropped to negative at SVR24. 
Low baseline platelet (PLT) is the significant statistical correlation with relapse. 
The relapse rate in low (<100/nL) PLT patients (9.59%) was much higher than the 
relapse rate in patients who had PLT >100/nL (2.43%) (P<0.01). The patients with 
low platelets are also considered difficult to treat successfully (Werner et al., 2016). 
 Analysis the relapse rate correlation with genotype in this study, the GT3 had the 
largest relapse rate (6.98%), the relapse rate for GT1 was 3.01%. 
   The primary reason for relapse in DAAs treatment is resistance-associated 
variants (RAVs), which lead to virological failure (Sarrazin, 2016, Pawlotsky, 2016). 
The virological failure of GT3, GT1, liver cirrhosis may be caused by viral variants 
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resistant to NS5A inhibitors (Pawlotsky, 2016). RAV of NS3-4A protease inhibitor 
can be eliminated in blood within weeks or months (Pawlotsky, 2016). However, 
NS5A inhibitor RAV can exist in much longer time, even for several years 
(Pawlotsky, 2016). 
HCV kinetics are biphasic and include two stages (Neumann et al., 1998). In the 
first stage, the Hepatitis C virus RNA decline with significant speed and the virus 
replication is quickly prevented. The second stage is slower because virus decrease 
relies upon the immune system effectors (Neumann et al., 1998). In the treatment 
duration, the sensitive virus get eliminated quickly. However, the resistant variants 
still exist in the liver, and cannot be detected in peripheral blood during treatment, but 
replicate after treatment finished (Pawlotsky, 2016). Some re-treatment strategies 
were recommended for the few virological failures in DAA treatment (Pawlotsky, 
2016). 
 
4.7.  Coinfection with HIV  
Hepatitis C patients coinfected with HIV or HBV were increasingly concerned in 
recent years. There are about 2,278,400 HCV-HIV coinfected patients in the world, 
2.4% prevalence in HIV-infected individuals (Platt et al., 2016). In this study, six of 
the 437 HCV positive patients were coinfected with HIV, the prevalence is 13.7%. 
Patients with HIV coinfection showed a good treatment result, SVR12 rate was up to 
100% without relapse. Due to the small number of this group, it is hard to calculate 
the accurate SVR12 rate. One study showed similar SVR12 rate in hepatitis C patients 
coinfected with HIV vs. non-coinfected with HIV in patients with DAAs treatment 
regimens (Milazzo et al., 2017). Another study showed high cure rates of 92% SVR12 
in a HCV-HIV coinfected cohort (Hawkins et al., 2016).  
 
4.8.  Coinfection with HBV 
There were only two hepatitis C patients coinfected with HBV, and one of them 
relapsed. The 50% relapse rate cannot represent the real success rate because the 
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number of this group is too small. In last two years, some studies have reported that 
DAAs can lead to reactivation of Hepatitis B virus (Wang et al., 2017, 
Bersoff-Matcha et al., 2017, De Monte et al., 2016). In HCV patients coinfected with 
HBV, the HBV DNA usually fluctuates greatly and cannot be detected. The hepatitis 
activity in coinfection patients is primarily driven by HCV (EASL, 2017) The risk of 
HBV reactivation after HCV elimination is still existing but unpredictable (Saadoun et 
al., 2015). This kind of HBV reactivation may happen in both HBsAg-positive and 
HBsAg-negative patients. HCV coinfection with HBV may lead to hepatocellular 
carcinoma and serious liver diseases (Sagnelli et al., 2002). In coinfection cases, it is 
necessary to evaluate the extent of HBV reactivation and to consider whether to 
optimize the treatment regimens. (EASL, 2017) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
5.  Summary 
 There are approximately 185 million HCV infected people all over the world. A 
serious problem of HCV infection is the high chronicity rate of about 80% 
HCV-infected patients may develop liver cirrhosis or hepatocellular carcinoma.  
The HCV standard therapy with interferon and ribavirin was used since1990s, the 
success rate of this treatment was only about 50%, and it was HCV genotype 
dependent. This changed significantly since the direct-acting antivirals (DAAs) 
became available from 2014 onwards. The success rate is about 95% and can be 
achieved in a very short time. 
In this study, 437 patients with HCV infection who were treated at the University 
Hospital Tübingen in the period from Jan. 2014 to April 2017 were analyzed. In the 
cohort, six patients were coinfected with HIV and two patients were coinfected with 
HBV. The rate of coinfection was relatively low because of the specific patient 
population of the Tübingen University Clinic. In larger cities, the prevalence of HBV 
and especially HIV infection is higher. In this cohort, 15 patients relapsed after the 
treatment and the HCV RNA was detectable in the blood. These 15 patients are 
analyzed during treatment and after treatment with respect to multiple factors such as 
viral load. 
Since different treatment regimens and treatment durations (8 weeks, 12 weeks, 
24 weeks) were used, these were related to laboratory and clinical parameters such as 
HCV genotypes, age, and gender of the patients, coinfections, etc. 
The most striking correlation was seen between relapse and liver cirrhosis. This 
also explained the unexpected finding that the patients with the longer treatment of 24 
weeks treatment duration had a higher relapse rate than the patients with 8 weeks or 
12 weeks duration. However, the 24 weeks treatment duration is mainly consisted by 
liver cirrhosis patients. 
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The analysis in this study shows impressively quick treatment success rate of 
95.95% of the new direct-acting antivirals (DAAs) in HCV infected patients. The 
liver cirrhosis patients and the low PLT patients had the lower success rate. 
 
 
5.  Zusammenfassung 
 
Hepatitis C Viren sind weltweit verbreitet und es werden 185 Millionen infizierte 
Menschen geschätzt. Ein wesentliches Problem der HCV Infektion ergibt sich durch 
die hohe Chronizitätsrate von ungefähr 80%, auf deren Boden Leberzirrhose oder 
auch Leberzellkarzinome entstehen können. Zunächst gab es in den 1990er Jahren 
Therapie mit Interferon kombiniert mit Ribavirin. Die Therapieerfolge lagen jedoch 
nur bei 50 % und waren HCV Genotyp abhängig. Dies änderte sich wesentlich 
seitdem die direkt wirksamen antiviralen Substanzen (DAAs) ab 2014 verfügbar 
wurden. Mit diesen DAAs werden Therapieerfolge/Heilung  von ungefähr 95 % in 
sehr kurzer Zeit erreicht.  
In dieser Arbeit wird die Auswertung von 437 Patienten mit chronischer 
HCV-Infektion, die am Universitätsklinikum Tübingen in der Zeit von Jan. 2014 bis 
April 2017 behandelt wurden, analysiert. Bei sechs Patienten lag eine Koinfektion mit 
HIV vor und bei zwei Patienten eine Koinfektion mit HBV. Die Koninfektionsraten 
waren relativ niedrig, welches an der Patientenkohorte des Universitätsklinikums 
Tübingen liegen dürfte. In größeren Ballungsräumen ist die Prävalenz von HBV und 
insbesondere HIV Infektionen deutlich höher. In 15 Patienten gab es einen Relapse 
und nach Beendigung der Therapie wurde die HCV RNA wieder im Blut nachweisbar. 
Diese 15 Patienten sind unter Therapie und nach Therapieende bezüglich der HCV 
Viruslast detailliert dargestellt. Da verschiedene Therapiekombinationen und 
insbesondere auch Therapiezeiten (8 Wochen, 12 Wochen, 24 Wochen) zur 
Anwendung kamen,  wurden diese mit anderen Parametern wie HCV Genotypen, 
Alter und Geschlecht der Patienten, Koinfektionen und andere klinische Daten in 
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Bezug gesetzt. 
Die auffälligste Korrelation zwischen Relapse und anderen Parametern ergab 
sich mit der Diagnose Leberzirrhose. Dies erklärte auch den zunächst überraschenden 
Befund, dass die Patienten mit den beiden längeren Therapiezeiten eine höhere 
Relapse Rate hatten als die Patienten mit 8 Wochen Therapie. Die 
24-Wochen-Behandlungsdauergruppe bestand hauptsächlich aus 
Leberzirrhose-Patienten. 
Die Resultalte dieser Arbeit zeigen eindrucksvoll den raschen Therapieerfolg und 
die hohe Rate von 95.95 % des Therapieerfolges mit den neuen direkt wirksamen 
antiviralen Substanzen (DAAs) bei chronischen HCV Infektionen in den letzten drei 
Jahren. Deutlich wird auch, dass es gehäufter zu Therapieversagen kommt, wenn im 
Rahmen der chronischen Hepatitis C schon eine Leberzirrhose oder geringe PLT 
(Thrombozytenzahl) vorliegen. 
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